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Parkinsonʼs disease (PD) is the second most common neurodegenerative 
disease with a global prevalence of 2–3% in people above 65 years of age 
(Poewe et al., 2017). Neurological disorders are now the leading source of dis-
ability globally, among which the growth of Parkinsonʼs disease has been the 
fastest. From 1990 to 2015, the number of people with PD doubled to over 6 
million. Driven principally by aging, this number is projected to double again to 
over 12 million by 2040. Additional factors, including increasing longevity, 
declining smoking rates, and increasing industrialization could raise the burden 
to over 17 million (Dorsey et al., 2018). For most of human history, PD has 
been a rare disorder − about 15% of the patients have positive family history for 
PD, and 5−10% have a specific monogenetic subtype of the disease. However, 
demographic change and the byproducts of industrialization have generated a 
surge in PD numbers, calling for heightened activism, focused planning, and 
novel approaches (Kalinderi et al., 2016).  
Depression is a highly prevalent psychiatric disorder with a lifetime risk 
close to 20% and is associated with high levels of morbidity and mortality 
(Palazidou, 2012). PD is characterized by motor and non-motor features, in-
cluding cognitive and neuropsychiatric disturbances. A number of studies have 
demonstrated the high prevalence of depression in patients with PD: epidemio-
logical research has reported that the frequency of severe forms of depression is 
5–20%, with milder forms occurring in an additional 10–30% of patients 
(Weintraub & Burn, 2011). A systematic review reported that premorbid 
depression was significantly more common in PD patients than in those without 
a diagnosis of PD, which suggests that depression may increase the risk of PD 
(Ishihara & Brayne, 2006). In a meta-analysis by Wang et al. (2018), depression 
was associated with a 2.2-fold increase in the incidence of PD. Despite the fre-
quent occurrence of depression in patients with PD, the Global Parkinsonʼs 
Disease Survey Steering Committee (2002) reported that only 1% of patients 
with PD recognized that they had depression. Depressed patients are at higher 
risk of serious physical health problems and worsening of the prognosis of other 
medical conditions (Palazidou, 2012), such as PD. Depression is a major factor 
in health-related quality of life (HR-QoL) in patients with PD (Jones et al., 
2015), and may also be associated with more rapid deterioration in motor and 
cognitive functions (Ng et al., 2015; Santangelo et al., 2009). Depression in PD 
has also been associated with the severity of PD and the level of disability 






































































Follow-up studies show depression to be a long-term, relapsing condition with a 
tendency towards chronicity, and the risk of recurrence increases with each new 
episode (Palazidou, 2012). Three quarters of the patients experience more than 
one episode of depression, and the risk of recurrence is higher if the first epi-
sode occurs at a younger age and if there is a family history of depression 
(Hollon et al., 2006). Given these findings, the need for effective treatment 
starting from the first episode of depression is of critical importance. Mainte-
nance treatment for several months during remission is essential after an acute 
episode of depression to prevent relapse, as well as long-term treatment to pre-
vent recurrence in patients with more than one episode (Glue et al., 2010). In 
addition to the number of episodes, the prognosis is influenced by the duration 
of illness remaining untreated; the more protracted this is, the poorer the 
response to treatment and the lower the likelihood of achieving remission 
(Okuda et al., 2010). Subsyndromal states encourage relapse and progression to 
chronicity (Pintor et al., 2003). According to Palazidou (2012), many patients 
do not achieve full remission for various reasons which include poor com-
pliance, premature ending of treatment, the use of inadequate treatment and 
other factors. Also, long-term depression (over 2 years) is common, clinically 
more serious than episodic depression, and associated with more functional 
impairment and high comorbidity. As the symptoms of depression increase 
during the progression of PD, they also raise direct healthcare costs such as 
examinations and treatment, and indirect costs such as disability-related job loss 
and caregiver burden (Huse et al., 2005; Johnson et al., 2013), causing prevent-
able social expenditure at the national level. Multiple treatment types exist for 
depressed patients with PD, including pharmacotherapy, psychotherapy, and 
brain stimulation. Despite the substantial number of studies of PD-related 
depression in specific, its precise role in PD and respective treatment methods, 
especially newer ones such as repetitive transcranial magnetic stimulation, are 
insufficiently understood, and underdeveloped. 
 
 
1.1. Key aspects of Parkinsonʼs disease 
In PD and related synucleinopathies, treating motor signs and symptoms (such 
as tremor, muscle rigidity, and bradykinesia, but also motor fluctuations and 
dyskinesias) resulting from the degeneration of dopaminergic neurons in the 
substantia nigra has long been the focus of disease management. However, in 
recent years, because of increased clinical recognition and relevance to the pa-
tientʼs quality of life, the non-motor aspects of such disorders have attracted 
increasing interest (Takamatsu et al., 2018).  
Non-motor symptoms (NMS) in PD are common and contribute to di-
minished HR-QoL, increased dependency on caregivers, greater cognitive 
impairment, and more frequent subjective motor symptoms (Dhingra et al., 
2021). According to the 2015 criteria by the Movement Disorder Society, the 
12 
core feature of PD is parkinsonism as defined by bradykinesia in combination 
with either resting tremor, rigidity, or both (Postuma et al., 2015). However, 
NMS are now being recognized as additional criteria within the prodromal pe-
riod of PD. 
Clinically, PD-related NMS consist of four domains: neuropsychiatric (e.g., 
depression, anxiety, apathy, hallucinations, mild cognitive impairment, demen-
tia), autonomic (e.g., constipation, orthostatic hypotension, urinary changes, and 
sweating abnormalities), sleep (e.g., insomnia, sleep fragmentation, excessive 
daytime sleepiness, rapid eye movement sleep disorder, and restless leg syn-
drome), and sensory dysfunction (e.g., pain and olfactory dysfunction) (van 
Rooden et al., 2009; Modugno et al., 2013; Pellicano et al., 2015). Such diver-
sity of NMS may be consistent with the widespread distribution of alpha-synu-
clein (αS) pathology in the gut (Shannon & Vanden Berghe, 2018; Stolzenberg 
et al., 2017) as well as in the brainstem and neocortex (Hawkes et al., 2007), in 
which multiple populations of aminergic neurons may be affected. In regard to 
cognition, the dopaminergic system of the brain is believed to be strongly in-
volved in normal and pathological behavioral phenotypes of attention. 
Consequently, in addition to PD, other synucleinopathies such as dementia 
with Lewy bodies and multiple system atrophy are associated with a wide range 
of non-motor symptoms, including cognitive impairment, depression and anxie-
ty, sleep disorders, gastrointestinal symptoms, and autonomic failure. Thus, the 
classic Parkinsonian motor syndrome is now regarded as but one unitary symp-
tom type among many disparate symptoms of these types of neurodegenerative 
diseases (Takamatsu et al., 2018). 
 
 
1.2. Neuropsychiatry of Parkinsonʼs disease 
Neuropsychiatric disorders (such as affective, behavioral, and cognitive symp-
toms) are important non-motor features in PD, which occur at high frequency 
and have significant impact on the degree of disability and quality of life 
(Figure 1). These frequently affect PD patients from the very first stages of the 
disease, or even before the onset of motor symptoms (Baig et al., 2015; Kalia & 
Lang, 2015; Pont-Sunyer et al., 2015). Despite their major impact on the quality 
of life of patients with PD, they are underrecognized and untreated (Bologna et 
al., 2019), or the treatment may not be optimal. 
Although PD is still considered a movement disorder and is diagnosed based 
on cardinal motor signs and symptoms (Postuma et al., 2015), the high preva-
lence of numerous neuropsychiatric symptoms suggests that it is more suitably 
conceptualized as a neuropsychiatric disorder (Weintraub & Burn, 2011). Ac-
cording to a study by Aarsland and colleagues (1999), the overall prevalence of 
neuropsychiatric symptoms in PD patients was 61%. The most common symp-
toms were depression (38%), hallucinations (27%), anxiety (20%) and apathy 
(16.5%). The less common symptoms are euphoria (7.0%) and disinhibition 
(6.5%). A later study (Aarsland et al., 2009) found that the prevalence of neuro-
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psychiatric symptoms in early untreated PD patients was 56%. The most com-
mon symptoms reported in this study were depression (37%), apathy (27%), 
sleep disturbance (18%) and anxiety (17%), whereas psychotic symptoms were 
found to be very rare among untreated PD patients. For many PD patients and 
their families, neuropsychiatric disturbances are often more problematic and 
distressing than the motor aspects of disease (Hely et al., 2005). 
According to Schrag and Quinn (2020), the focus of clinical management 
and treatment trials in PD in the early 1990s had been the development of better 
management options for the motor features and complications of therapy, such 
as motor fluctuations and dyskinesias. Clinical assessment, and in particular 
clinical trials, almost entirely relied on clinicians’ judgement of severity of dis-
ease and its complications. However, in the late 1990s, this had started 
changing and the development of standardized scales to assess how patients 
evaluate their own health problems (i.e., HR-QoL measures) had recently en-
abled standardized quantitative assessment of patientsʼ views. HR-QoL scales 
made it possible to assess impact on patientsʼ lives, independent from clini-
ciansʼ assessments, and to incorporate other aspects of HR-QoL, such as the 
emotional and social impact of the disease. While overall disability was an im-
portant factor, the key and overwhelmingly determining feature associated with 
poorer HR-QoL was the severity of depressive features, as assessed on the Beck 
Depression Inventory. Depression had been recognized as associated with PD 
but was often considered a consequence (Brown & Jahanshahi, 1995) although 
it had also been seen as a manifestation of brain dysfunction (Tandberg et al., 
1997). We now know that, at least in part, it is an integral feature of the disease, 
and is significantly more common many years before the diagnosis (Ishihara & 
Brayne, 2006; Schrag et al., 2015) in people with a later diagnosis of PD than in 
controls. 
Depression has been the most widely studied of all psychiatric disorders in 
PD (Weintraub & Burn, 2011), and major advances have been made in charac-
terizing its frequency, clinical phenotype, and diagnosis (Weintraub, 2020). 
Worldwide, approximately 35–42% of PD patients have clinically significant 
depressive symptoms and 17–25% meet criteria for a major depressive disorder, 
which is notably higher than the prevalence rate of 13.5% in the general popula-
tion (Beekman et al., 1999; Hely et al., 2005; Dissanayaka et al., 2011; Marsh, 
2013; Pachana et al., 2013). Earlier epidemiological research has reported that 
the frequency of major (i.e., more severe) depression is 5–20%, with non-major 
forms (i.e., minor depression) occurring in an additional 10–30% of PD patients 
(Tandberg et al., 1996; Starkstein et al., 1998; Reijnders et al., 2008). Thus, up 
to 50% of PD patients experience depression at some point in the course of their 
illness. This is much higher than the prevalence of depression in adults in the 
local community (<10%) (Tandberg et al., 1996). Parkinsonʼs patients with 
depression have significantly higher anxiety symptoms, pessimism, suicidal 
thoughts, and self-condemnation compared to Parkinsonʼs patients without 
depression (Cummings, 1992; McDonald et al., 2003). Lee and colleagues 
(2016) analyzed 4,362 patients with PD and reported that the elderly with PD 
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had a two-fold higher risk of suicide compared to elderly without PD. In spite 
of the notions stated above, depression related to PD still remains underrecog-
nized and undertreated (Althaus et al., 2008), even in specialty care settings 
(Shulman et al., 2002; Weintraub et al., 2003). 
In a recent study by Fan et al. (2020), it was found that depression imposes a 
greater impact on PD patientsʼ HR-QoL than motor function when co-occurring 
with cognitive impairment. Mild cognitive impairment related to PD (PD-MCI) 
is common − a relatively recent systematic review and meta-analysis (Saredakis 
et al., 2019) found that within three years, in those with PD and normal cogni-
tion, 25% converted to PD-MCI and 2% converted to dementia. Of those with 
PD-MCI, 20% converted to dementia while 28% reverted back to a state of 
normal cognitive function. After three or more years, the conversion rates to 
MCI and dementia were higher, and reversion rates lower. Although the cogni-
tive deficits in PD have traditionally been classified as being “subcortical” in 
nature (i.e., relatively greater impairments in executive abilities, information‐
processing speed, and working memory compared with cortical functions like 
episodic memory storage and language skills), a review by Litvan and col-
leagues (2011) showed that a range of other cognitive domains are impaired in 
PD patients without dementia, including visuospatial, memory, and even lan-
guage abilities. In addition, bradyphrenia as slowing of perceptual-cognitive 
information processing has been previously described in PD (Ransmayr et al., 
1990; Bachmann et al., 1998; Shipley et al., 2002). 
In addition to the most commonly studied neuropsychiatric symptoms such 
as depression, cognitive impairment (both mild cognitive impairment and 
dementia), and psychosis, other relatively common and clinically significant 
psychiatric complications include impulse control disorders, various anxiety 
symptoms, disorders of sleep and wakefulness, and apathy. A recent study 
(Kuhlman et al., 2019) suggested that in mild to moderate PD, in addition to the 
disability related to motor dysfunction, the most significant predictors of HR-
QoL in PD are depression, anxiety, apathy, and excessive daytime sleepiness. 
The authors also pointed out that the non-motor symptoms of depression, anxie-
ty, apathy, and excessive daytime sleepiness as a group accounted for 48% of 
the variance in HR-QoL in PD. A systematic review of studies using regression 
analysis to determine the impact of specific neuropsychiatric symptoms on HR-
QoL in PD found depression to be most commonly associated with worse quali-
ty of life, and the most significant predictor of quality of life (Balestrino & 
Martinez-Martin, 2016). 
As described by Gallagher and Schrag (2012), the pathophysiology of neuro-
psychiatric symptoms is complex, reflecting the widespread brainstem and 
cortical pathology in PD, with involvement of several neurotransmitters, among 
which dopaminergic, serotonergic, noradrenergic and cholinergic systems are 
found to be involved most often. The diagnosis of psychiatric conditions, in 
particular affective disorders, is challenging because of the overlap of somatic 
features of psychiatric disorders with the underlying movement disorder. The 
pathogenesis is likely to differ considerably from non-PD patients, and treat-
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ments used in general psychiatry services may not be as effective in PD, war-
ranting further elaboration in well-designed clinical studies. In order to under-
stand the pathophysiology of PD better, brain imaging methods have become 
increasingly applied (Hu et al., 2015; Lou et al., 2015; Borgonovo et al., 2017; 
Nagy & Schrag, 2019; Lin et al., 2020). According to a systematic review by 
Wen and colleagues (2016), increased neural activity in the prefrontal regions 
and decreased functional connectivity between the prefrontal limbic networks in 
depressed patients have been consistently noted in previous research. Functional 
imaging studies point at an inverse correlation between dopaminergic density in 
the caudate and putamen with the severity of anxiety in PD. Prefrontal control 
of the patientʼs state in the combined PD and depression is clearly evident as 
shown in these studies, suggesting forms of treatment by intervention through 
manipulations of prefrontal functionality. This dissertation will delve into func-
tional connectivity in more detail in later chapters. 
Affective disorders (such as depression and anxiety), psychosis, impulse 
control disorders, and apathy are common and sometimes disabling psychiatric 
conditions in PD. There is inconsistent evidence that depression related to PD is 
distinct from clinical (i.e., non-PD) depression; some studies report higher rates 
of anxiety, pessimism, suicide ideation without suicide behavior, and less guilt 
and self-reproach in depressed PD patients compared with their non-PD 
counterparts (Leentjens, 2004). However, overall predictors or correlates of 
depression are similar between populations (Leentjens et al., 2013). Psychiatric 
aspects of PD are frequent and associated with numerous adverse outcomes, yet 
there remains incomplete understanding of their epidemiology, presentation, 
risk factors, neural substrate, and management strategies (Weintraub, 2020). 
Psychiatric features are typically co- or multimorbid, and there is great intra- 
and interindividual variability in presentation (Martinez-Martin et al., 2020). A 
significantly higher risk of anxiety and depression among the first-degree rela-
tives of patients with PD has been shown, providing evidence for shared genetic 
and/or common environmental factors (Arabia et al,, 2007). With the introduc-
tion of levodopa and other medications and treatments into clinical practice, the 
increasing life span of both the general population and patients, and growing 
awareness and clinical research in the past half-century, PD-related neuro-
psychiatric disorders have been recognized as being very common and disabling 
long-term complications (Chaudhuri et al., 2006). In addition, they are associated 
with poor long-term outcomes and increased caregiver burden, requiring special 
clinical expertise for optimal management (Weintraub & Burn, 2011). 
 
 
1.3. Treatment of neuropsychiatric symptoms of 
Parkinsonʼs disease 
Two major complementary paradigms have guided treatment development for 
neuropsychiatric disorders for nearly 70 years: a neurochemical paradigm 
positing that neuropsychiatric dysfunction results from abnormalities of (pri-
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marily) neurotransmitters, and a behavioral/psychological paradigm purporting 
that dysfunction results from alterations of emotions, thought, and learning. The 
first has given rise to dozens of pharmacological agents to prevent and/or treat 
neuropsychiatric conditions, while the second has resulted in numerous psycho-
therapeutic approaches. Although these interventions are generally effective for 
most individuals with neuropsychiatric disorders, a substantial minority of 
patients continue to suffer despite treatment (Slaughter et al. 2001; Chen & 
Cheng, 2008; Lesenskyj et al., 2018).  
Pharmacological agents used for the treatment of depression in general 
psychiatry practice include tricyclic antidepressants (TCA), the tricyclic-related 
drugs (e.g., trazodone), the selective serotonin reuptake inhibitors (SSRI), the 
serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine, the selective 
noradrenaline reuptake inhibitor (NRI) reboxetine, the presynaptic alpha-2 
adrenoreceptor antagonist mirtazapine and the noradrenaline–dopamine reup-
take inhibitor (NDRI) bupropion. All of them may have a role in treatment of 
mood disorders in PD. Approximately 20–25% of PD patients are on an antide-
pressant at any given time, even de novo, untreated patients (Smith et al., 2015; 
Martinez-Martin et al., 2020), most commonly a SSRI (Richard et al., 1997; 
Weintraub et al., 2003). Zhuo and colleagues (2017) completed a meta-analysis 
on the efficacy of antidepressant medications and found SSRIs to be most 
efficacious, however, they had more adverse effects compared to SNRIs which 
were considered the safest. Antidepressant use increases over the initial years of 
PD (Caspell-Garcia et al., 2017). Adverse effects of these medications can 
however limit their use, particularly in the elderly. According to Gallagher and 
Schrag (2012), autonomic phenomena commonly encountered in PD, such as 
orthostatic hypotension, are prone to exacerbation by the anti-cholinergic 
effects of TCAs, and to a lesser extent, SSRIs. The anti-cholinergic action of 
these drugs may worsen neuropsychiatric features of PD, such as cognitive 
impairment, visual hallucinations, and delusional thoughts. The SSRIs have 
important pharmacological interactions with the MAO-B inhibitors selegiline 
and, to a lesser degree, rasagiline, and thus theoretical predilection to serotonin 
syndrome. 
Many depressed PD patients do not respond to pharmacotherapy or are 
reluctant to take additional medications, and thus may prefer psychotherapy 
(Oehlberg et al., 2008), which constitutes the second approach to depression 
treatment. Cognitive-behavioral therapy (CBT) has been shown to be effica-
cious for PD-related depression; for example, the results of a large RCT (n=80) 
using CBT showed Hamilton Depression Rating Scale (HAM-D) depression 
scores significantly decreased and symptoms remained stable at 1-month 
follow-up (Dobkin et al., 2011). Support is also present for group CBT for treat-
ment of both depression and anxiety among patients with PD, with results main-
tained at 6-month follow-up (Troeung et al., 2014). Improvements through CBT 
have been seen not only in mood, but also in verbal memory and executive 
functioning (Dobkin et al., 2014). A fairly recent meta-analysis concluded that 
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exercise appears to have an impact on depressive symptoms in PD (Wu et al., 
2017), but overall, it seems that the scientific evidence for this notion is limited.  
The third approach to depression treatment development proposes that 
neuropsychiatric disorders result from the dysfunction of specific brain regions 
and/or networks of regions (Holtzheimer, 2018). Cortical dysfunction has been 
documented in PD by neuroimaging and neurophysiologic studies, showing 
either hypo- or hyperactivation of various brain areas (Lefaucheur, 2006; Lefau-
cheur, 2009). Both invasive and non-invasive brain stimulation methods can 
counter this imbalance in electrophysiological properties. In medicine, the term 
‘invasive’ typically refers to procedures that breach the biological tissue or re-
quire implantation of a device into the body. Deep brain stimulation (DBS) is an 
established, although invasive treatment for PD that has been used for more 
than three decades. Although the mechanisms of DBS are still not fully under-
stood, both subthalamic nucleus (STN) and internal globus pallidus (GPi) are 
effective targets to ameliorate complications such as motor fluctuation and 
dyskinesia related to long-term use of levodopa. In a study by Rätsep and Asser 
(2011), a comparison of mean clinical motor scores of six PD patients revealed 
a significant improvement of parkinsonian symptoms (in particular, arm rigidi-
ty) after DBS of the STN, also confirming that myotonometry is an objective 
method to evaluate rigidity in patients with PD. DBS has also been associated 
with improvement in mood, with mixed evidence from two meta-analyses that 
GPi lead location is preferred over the STN (Sako et al., 2014; Wang et al., 
2016); if true, this is perhaps because GPi-stimulated patients undergo a smaller 
postoperative decrease in their PD medications (Weaver et al., 2009). For a 
review of clinical and electrophysiological effects and the future directions of 
invasive brain stimulation in PD (including DBS), see the work by Chen and 
Chen (2019). 
Invasive brain stimulation techniques may not be an option for everyone, so 
non-invasive brain stimulation (NIBS) methods have also been developed. 
Although being one of the most used and highly effective NIBS techniques 
available for treatment-resistant depression, modern electroconvulsive therapy 
(ECT) has been associated with adverse cognitive effects that can lower the 
patientʼs quality of life. Less is known about ECT usage in PD. For severe, 
treatment resistant PD-related depression, ECT has been shown to be somewhat 
effective (Popeo & Kellner, 2009). There is still a growing need to safely, toler-
ably, and with minimal adverse effects help PD patients overcome treatment-
resistant depression. NIBS techniques such as repetitive transcranial magnetic 
stimulation (rTMS) and transcranial direct current stimulation (tDCS) have 
shown promise in addressing the fronto-striatal neural network via stimulation 
of the DLPFC (Kanno et al., 2004; Marcolin & Padberg, 2007), impacting cog-
nitive as well as affective symptoms (Schulz et al., 2013). The basic principle of 
transcranial magnetic stimulation (TMS) is the application of short magnetic 
pulses over the scalp of a subject with the aim of inducing electrical currents in 
the cortical neurons of a predefined brain area. In a single-pulse TMS protocol, 
only a single impulse is applied. The objective is to measure the stimulation 
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effect on brain processes and/or behavior. In parallel, rTMS, first introduced in 
1989, is a non-invasive technique of repeated stimulation of the cerebral cortex 
by a train of magnetic pulses. Since then, a large number of studies have in-
volved rTMS as an investigational tool as well as a potential treatment for a 
variety of neurological and psychiatric disorders (Kamble et al., 2014). Since 
receiving FDA clearance as a reimbursable therapeutic method for treatment-
resistant unipolar depression in 2008, rTMS has also stated to gain momentum 
as an attractive treatment method to alleviate other neuropsychiatric problems, 
including those associated with PD.  
 
 
1.4. Aims of the thesis 
As introduced in the preceding sections of this dissertation, depression is 
recognized as the most common neuropsychiatric symptom in PD. Depression 
in the context of PD is cause for concern because of associated faster cognitive 
and motor decline (Starkstein et al., 1992), poorer quality of life, and increased 
mortality (Hughes et al., 2004) seen in depressed patients with PD as compared 
to their non-depressed counterparts. Multiple treatment types exist for patients 
with PD-related depression, including pharmacotherapy, psychotherapy, and 
non-invasive brain stimulation. Advanced stage multimorbid PD patients with 
polypharmacy represent a relevant challenge for therapeutic safety (Chen & 
Cheng, 2008), and for achieving treatment response. 
The general aim of the dissertation was to summarize the evidence and, 
where possible and appropriate, to fill the gaps and expand on knowledge re-
garding the effective therapeutic application of rTMS in patients with depres-
sion related to Parkinsonʼs disease, with possible implications to neuro-
psychiatric phenomena outside the mood domain (e.g., cognitive impairment and 
anxiety), and consequently, the patientsʼ quality of life. The approach undertaken 
was threefold: (a) to collate, participate in the validation of, and synthesize the 
available scientific evidence regarding the neural circuitry of depression within 
the context of PD, (b) to analyze the feasibility and specific parameters of using 
rTMS to treat depression in PD, and (c) to apply the knowledge from the 
previous two points to a clinically complex and heterogeneous sample of PD 
patients with treatment-resistant depression, with a goal to assess the role of 
individual differences in treatment response and gather direct data on any 
emerging practical issues in using NIBS in the aforementioned clinical setting. 
The latter serves as proof-of-concept to be used subsequently for developing an 
optimal treatment protocol for PD-related treatment-resistant depression. 
Using transcranial sonography, it has been indicated that marked hyper-
echogenicity of the substantia nigra and reduced brainstem raphe echogenicity 
(suggestive of structural alterations at these sites) is particularly common and 
severe in patients who have both PD and depression, and these changes in the 
brain are associated with a history of depression before the development of PD 
(Walter et al., 2007a; Walter et al., 2007b). The precise nature of this relation-
19 
ship is not entirely clear. The specific aim of Study I was to describe the 
prevalence and severity of depressive symptoms in PD and to analyze possible 
associations between specific brain-based biomarkers – in this case, the brain-
stem raphe – and depressive symptoms. The main expectations of the study 
were to confirm that neuroanatomical alterations of raphe nuclei in the brain-
stem (expressed in echogenicity levels) are involved in the pathogenesis of 
depressive disorders in PD, and that the degree of these changes is directly 
related to depressive symptom severity. Understanding that depressive symp-
tom severity is an important factor modulating the clinical aspects of PD, an 
urgent need for new and effective treatments is raised (especially for PD 
patients with treatment-resistant depression). 
The hypoactivity of the dorsolateral prefrontal cortex (DLPFC) in depression 
has been identified by many previous studies and now regarded as a critical 
hallmark for depression (Ring et al., 1994; Dragaševic et al., 2002; Mottaghy et 
al., 2002; Fregni et al., 2006; Cardoso et al., 2008; Bench et al., 2009; Koenings 
& Grafman, 2009). The DLPFC is regarded as most accessible for treatment 
with rTMS (Wassermann & Lisanby, 2001). Study II was set out to pool the 
available scientific literature on the therapeutic usage of a specific NIBS 
technique – rTMS – on neuropsychiatric symptoms of PD specifically as-
sociated with the dorsolateral prefrontal cortex (i.e. depression and cognitive 
impairment). 
Following up on Study I and Study II and building on gained knowledge, the 
aim of Study III was to establish a preliminary effective, safe and tolerable 
evidence-based rTMS protocol for PD patients with treatment-resistant depres-
sion. Patients with PD-related TRD represent a heterogeneous clinical sample, 
stressing the interindividual variability in both clinical status and characteristics 
of treatment response. The study protocol will take these characteristics into ac-
count so as to be a viable approach in addressing PD-related treatment-resistant 
depression. The research questions addressed within the thesis are: 
1.  What is the current understanding of the neural circuitry of affective pro-
cessing in depression related to PD? 
2.  How does depression influence the overall disease trajectory and quality of 
life of PD patients? 
3.  Can a NIBS method such as rTMS effectively, safely, and tolerably be 
applied to treat depression related to PD? In addition to treating depression, 
is there evidence regarding the treatment of other common neuropsychiatric 
problems associated with PD using rTMS? 
4.  What are the known obstacles and emerging questions to be mindful of when 
using rTMS to treat PD patients with treatment-resistant depression? How 





2. INSIGHTS FROM AFFECTIVE AND  
COGNITIVE NEUROSCIENCE INTO DEPRESSION AND 
PARKINSONʼS DISEASE 
2.1. Neural circuits of affective processing 
The neural circuits of affective processing include the limbic system and the 
prefrontal cortex (PFC). These brain areas and their connections are collectively 
responsible for maintaining emotional equilibrium, and thus, their malfunction 
is considered central to the pathophysiology of depression (Palazidou, 2012). 
The limbic system is a set of brain structures located on both sides of the thala-
mus, immediately beneath the medial temporal lobe of the cerebrum primarily 
in the forebrain. It supports a variety of functions including the processing of 
emotions, behavior, motivation, long-term memory, and olfaction.  
The limbic system comprises of the amygdala, the cingulate gyrus, the hippo-
campus, the hypothalamus, and the anterior thalamic nuclei, as well as their con-
nections surrounding the brainstem. The amygdala is one of two almond-shaped 
clusters of nuclei located deep and medially within the temporal lobes of the 
brain. Its primary role lies in the processing of emotional learning and memory, 
decision-making and emotional responses (including fear, anxiety, and aggres-
sion). It is involved in recruiting and coordinating cortical arousal and neuro-
endocrine response to underdetermined (surprising and ambiguous) stimuli. It 
also has connections with cortical and subcortical areas thought to be engaged 
in attentional and motivational processes (Holland & Gallagher, 1999; Davis & 
Whalen, 2001). 
The PFC lies anteriorly to the premotor area (involved in the planning of 
complex motor actions) that itself is situated more rostrally from the primary 
motor area (involved in mediating conscious movement) of the frontal cortex. 
The PFC integrates complex sensorimotor information with motivation and 
affect. It is divided into three major sections: the dorsolateral, the paralimbic 
(orbital and medial aspects of PFC), and the anterior cingulate cortex (ACC) 
(Figure 2). The ventromedial (VMPFC) and the dorsolateral (DLPFC) prefron-
tal cortices connect with each other via the cingulate gyrus and the hippo-
campus. The VMPFC is necessary for the normal generation of emotions (in 
particular, social emotions) (Damasio et al., 1990) as well as the regulation of 
autonomic and neuroendocrine responses and modulation of pain, aggression, 
sexual and eating behaviours (Ongür & Price, 2000). The orbital PFC, or orbito-
frontal cortex (OFC), plays a role in correcting behavioural or emotional 
responses (generated in part by the amygdala), while the DLPFC has been 
consistently implicated in cognitive control, solving complex tasks, mainte-
nance and manipulation of information in working memory (Palazidou, 2012). 
According to Downar and Daskalakis (2013), the prefrontal regions do not 
function in isolation, but rather as nodes in larger networks involved in 
depression-related functions: cognitive control, rumination and self-reflection, 
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and the generation of visceral states sometimes known as somatic markers (Da-
masio, 1996). The anatomical projections from the medial prefrontal network to 
the amygdala, hypothalamus, periaqueductal grey (PAG), locus coeruleus, 
raphe nuclei, and brainstem autonomic nuclei play major roles in organizing the 




Figure 2. Maps of the orbital and medial surfaces of a human brain (above) and a 
macaque monkey brain (below), showing architectonic areas. The medial and orbital 
prefrontal networks are colored yellow and green, respectively. The networks have been 
defined based on connectional data. The regions referred to as the subgenual and pre-
genual anterior cingulate cortex (sgACC and pgACC) are indicated on the human brain 





Data from functional neuroimaging studies suggests that there is a complex 
network of brain regions that are involved in the pathophysiology of depression 
(Fitzgerald et al., 2008). Impaired reciprocal functional relationships between 
limbic (e.g., amygdala) and cortical (e.g., dorsolateral prefrontal cortex) struc-
tures are thought to correlate with emotional dysregulation and depression 
(Mayberg, 2003; Drevets et al., 2008). Functional neuroimaging studies have 
also implicated that variations in activity levels of the amygdala contribute to 
the development of depressive symptoms; for example, in depressed patients, 
Sheline and colleagues (2001) found a greater activation of the left amygdala 
during early stages of depression while also confirming that that after 8 weeks 
of antidepressant treatment, the activation decreased drastically. After increased 
amygdalar activation, decreased bilateral or left prefrontal cortical activation are 
also often reported functional anomalies in the imaging literature related to 
depression (Davidson et al., 2002a; Davidson et al., 2002b; Zhong et al., 2011). 
Because the DLPFC mediates a protective function against depression during 
the regulation of negative emotion (Phan et al., 2005; Eippert et al., 2007), 
hypoactivation in certain regions of the DLPFC could be linked to a failure to 
override other more automatic negative responses that might then lead to more 
severe negative mood states (Davidson et al., 2002a, Davidson et al., 2002b). 
These relationships will be further explored in the next sections of this chapter.  
 
 
2.2. Structural and functional connectivity  
in clinical depression 
The clinical phenomenology of depression implicates brain systems involved in 
the regulation of mood, anxiety, fear (e.g., panic attacks, phobias, and post-
traumatic stress syndromes commonly occurring co-morbidly with depression), 
reward processing, attention, motivation, stress responses, social interaction, 
and neurovegetative function (i.e., sleep, appetite, energy, weight, libido) 
(Victor, 2013). Structural magnetic resonance studies have shown a reduction in 
the brain volume of depressed patients compared with healthy controls, with 
large volume reductions in the ACC and OFC, and moderate reductions in the 
hippocampus, the putamen and the caudate (Koolschijn et al., 2009). Functional 
brain imaging studies in depressed patients have shown abnormalities in 
regional cerebral blood flow and glucose metabolism in multiple structures 
involved in emotion processing, such as the PFC, cingulate gyrus, OFC, or 
deeper limbic regions like the amygdala, insula and hippocampus (Fitzgerald et 
al., 2006a; Steele et al., 2007). Fluorodeoxyglucose positron emission 
tomography (FDG-PET) studies of resting brain function in depression reveal 
bilaterally observable net hypoactivity in a widespread network that includes, in 
addition to the DLPFC and VMPFC, the dorsomedial prefrontal cortex 
(DMPFC), frontopolar cortex (FPC), and ventrolateral prefrontal cortex 
(VLPFC), along with hypoactivity in partner regions in the precuneus, lateral 
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parietal lobes and middle temporal gyri, and increased activity of amygdala, 
hippocampus, and brainstem raphe nuclei (Li et al., 2010; Price & Drevets, 
2012). In depression, the VMPFC shows increased activity while the DLPFC 
shows a decrease in activity (Drevets, 1998). According to Palazidou (2012), 
decreased activity of the DLPFC in depression has been associated with 
psychomotor slowing and anhedonia. Response to treatment is associated with a 
decrease in metabolic activity, and long-term antidepressant drug treatment 
reduces metabolism in the amygdala and ACC in subjects with persistent, posi-
tive treatment response. In contrast, the persistence of the abnormal metabolic 
deficits in the dorsomedial/dorsal anterolateral PFC in depression during treat-
ment may relate to histopathological changes reported in these regions in post-
mortem studies (Drevets et al., 2002). The structural changes in the brain, parti-
cularly the hippocampus and PFC, are believed to arise due to abnormalities in 
neuroplasticity rather than neurodegeneration. Nevertheless, it remains to be 
confirmed whether these changes are indeed always reversible, particularly in 
the PFC and also whether or not they predate the onset of depression.  
 
 
Table 1. Functional and structural changes in the limbic and PFC areas implicated in 
depression (adapted from Palazidou, 2012, with permission). 
Substrate Volume Histological changes
Metabolic 
activity Antidepressant effects 
OFC/VMPFC ↓ ↓ ↑  
ACC ↓   ↓ Metabolic activity 
Hippocampus ↓ ↓  ↑ Volume 
Amygdala ↓?   ↓ Metabolic activity 
DLPFC ↓ ↓ ↓  
 
 
As summarized by Palazidou (2012), experimental lesioning studies, clinical 
observations of patients with degenerative disorders of the basal ganglia, and 
neuroimaging structural and functional studies in depressed subjects have 
provided strong evidence that deficits in normal functioning of the limbic-
cortico-striato-pallido-thalamic circuits related to the medial and orbital PFC 
networks are among the main causes of depression. Consequently, abnorma-
lities which interfere with the finely balanced interaction/communication within 
the neurocircuit, and in particular, a decrease in the inhibitory control of the 
limbic structures by the PFC, is associated with the characteristic emotional 
processing, cognitive performance, behavioral and other signs of depression as 
well as abnormalities in neurotransmitter activity, neuroendocrine function and 
pain modulation. Price and Drevets (2012) have proposed that impaired 
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function within the circuits involving the medial prefrontal network and related 
limbic structures can account for these disturbances in mood disorders.  
The limbic-cortico-striato-pallido-thalamic circuit (Figure 3) is responsible 
for maintaining emotional stability and appropriate responses to emotional 
stimuli as well as regulating neurotransmission, autonomic and neuroendocrine 
function. This system also links with relevant structures in the midbrain/brain-
stem (for example, the serotonergic raphe nuclei and the adrenergic locus 
coeruleus). In healthy humans, frontostriatal circuitry plays a crucial role in 
several different processes such as emotion, motivation and executive functions, 
including set-shifting, working memory and decision-making; this is probably 
because of its looped structure with cortical inputs to the striatum from where 
signals are projected back to the cortex via the thalamus (Alexander et al., 1986; 
Alexander & Crutcher, 1990). It has been hypothesized that in the depressed 
state the balance amongst the structures within the neurocircuit is disrupted as a 
result of decreased activity in the PFC which impairs its regulatory (inhibitory) 
action on the limbic structures which then become overactive. This dysregula-
tion then leads to the manifestation of depressive symptoms (Palazidou, 2012). 
One of the key questions in psychophysiology research concerns how 
individual differences in hemispheric asymmetry are manifested in motivation 
and personality. One dominant theory elaborated by Gray and colleagues, 
named the “reinforcement sensitivity theory” (Gray, 1982; Gray, 1987; Gray & 
McNaughton, 1996; Corr, 2004; McNaughton & Corr, 2004), suggests the 
operation of two general systems for coordinating adaptive behavior. The first 
system is referred to as the Behavioral Inhibition System (BIS). This system is 
sensitive to signals of conditioned punishment, non-reward, novelty, and innate 
fear stimuli. Its function is to increase attention toward aversive stimuli, to 
interrupt ongoing behavior and prepare for vigorous action or withdrawal, while 
processing potential threat cues. BIS is involved in the control of impulsive 
behavior. A second system has been referred to as the Behavioral Activation 
System (BAS) (Fowles, 1980; Fowles, 1988) or, alternatively, the Behavioral 
Approach System (Gray, 1982). The BAS is believed to mediate the experience 
of positive affect and behavioral disinhibition (ʼappetitiveʼ behavior). Individual 
variation in the BAS predicts approach-related behavior and positive emotion in 
response to reward cues. Alpha band power is inversely related to activation 
(Lindsley & Wicke, 1974) and has been the measure most consistently used in 
studies of EEG asymmetry (Davidson, 1988) as a signature of BIS/BAS relative 
impact on the behavioral state and disposition. Davidson, and colleagues (1979) 
derived a measure of frontal alpha asymmetry to make inferences about 
emotional processes by subtracting alpha power of the left PFC from alpha 
power of the right PFC as a straightforward index. Positive emotional states 
have been found to be associated with a left > right activation asymmetry 
(Harmon-Jones & Allen, 1998; Harmon-Jones & Sigelman, 2001), whereas 
negative emotional states with a right > left activation asymmetry (Henriques 
and Davidson, 1990; Henriques & Davidson, 1991; Davidson & Henriques, 
2000). Higher BIS scores have been associated with greater right PFC activity 
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(Shackman et al., 2009) whereas greater left PFC is associated with higher BAS 
scores (Harmon-Jones & Allen, 1997; Coan & Allen, 2003; Amodio et al., 
2008; De Pascalis et al., 2013). In depressed individuals, BIS scores have been 
directly associated with depression severity (Wang et al., 2017). Higher BIS 
sensitivity may increase the avoidance goals and behaviors and amplify 
affective reactions to negative events (Gable et al., 2000) and is responsible for 
the excessive negative emotion observed in MDD. Consistently with this and 
with the theory, lower BAS functioning may be associated with approach 
deficits which limit the access to positive emotion and rewarding experiences 
(Trew, 2011) and in turn lead to sustained negative affect. According to a study 
by Wang et al. (2017), due to the evidence that prefrontally mediated cognitive 
control can either inhibit or augment reactions to achieve successful goal-
directed behavior (Eippert et al., 2007), the altered prefrontal emotion regu-
latory network (DLPFC/VMPFC/VLPFC) in depressed patients demonstrated 
ineffective top-down modulation of emotion, as well as impaired modulatory 
role of approach/avoidance motivation in emotion regulation. 
 
 
2.3. Structural and functional connectivity in  
depression as related to Parkinsonʼs disease 
Although the exact pathogenesis of behavioral and emotional disorders as-
sociated with PD remains to be clarified, several contributing mechanisms have 
been observed (Bologna et al., 2019). Several mechanisms have been proposed, 
including dopaminergic and nondopaminergic dysfunctions of several pathways 
at the subcortical and cortical levels, including in the limbic system (Diederich 
et al., 2016; Péron et al., 2012). In 1995, a unifying model of neurodegeneration 
in depression and PD was proposed (Mayberg & Solomon, 1995). This model 
suggests that primary degeneration of dopaminergic mesocortical and meso-
limbic neurons leads to dysfunction of the orbitofrontal cortex, which secon-
darily affects serotonergic cell bodies in the dorsal raphe nuclei. Additional 
circuits that are proposed to be affected in patients with depression include the 
basotemporal limbic circuit, which links the orbitofrontal cortex to the anterior 
temporal cortex through the uncinate fasciculus, and the orbitofrontal cortex–
basal ganglia–thalamic circuit. This model has received partial support from 
subsequent studies showing that patients with PD and depression had a pro-
found loss of striatal dopamine transporter availability (Weintraub et al., 2005b) 
and frontal hypoperfusion compared with nondepressed PD patients (Matsui et 
al., 2006).  
Because of the complex and important role of the basal ganglia in processing 
a wide range of motor and non-motor information (Grillner & Robertson, 2016; 
Stephenson-Jones et al., 2011), dysfunction in these structures is thought to play 
a key role in generating behavioral and emotional disorders in PD. It is believed 
that functional alterations in basal ganglia nuclei are relevant in the etiopatho-
logy of movement disorders such as PD. The main assemblages of serotonin-
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synthesizing neurons are located in the brainstem raphe nuclei whose neurons 
receive efferents from the peripheral and the central nervous system, including 
the substantia nigra. Neurons from the dorsal raphe nuclei send descending and 
ascending projections to innervate almost all brain areas, including the basal 
ganglia. The basal ganglia form a complex, highly organized subcortical net-
work that connects the thalamus with the cortex and plays an important role in 
the control of motor behavior, emotion and cognition. The main components of 
the basal ganglia are the striatum, consisting of both the dorsal (caudate nucleus 
and putamen) and the ventral part (nucleus accumbens and olfactory tubercle), 
the globus pallidus, the ventral pallidum, the substantia nigra, and the sub-
thalamic nucleus (Fix, 2008). The substantia nigra consists of two parts: pars 
reticulata and pars compacta. The latter region provides dopaminergic input into 
the basal ganglia, and when it degenerates, it leads to neuronal dysfunction in 
these nuclei. In the classical basal ganglia model (Alexander et al., 1986), the 
loss of dopaminergic neurons in PD leads to disinhibition of the indirect path-
way and a reduction in the inhibitory action of the direct pathway, resulting in 
elevated activity of the output nuclei (the substantia nigra, pars reticulata and 
the internal segment of the globus pallidus). The augmented activity of the basal 
ganglia output structures, which are inhibitory, reduces motor activity, resulting 
in PD motor symptomatology. By contrast, levodopa administered to treat PD 
symptoms causes the opposite effect of dopaminergic neuron loss, producing a 
decrease in the basal ganglia output nuclei activity (Aristieta et al., 2016; Obeso 
et al., 2008). 
During the last decades, substantial knowledge concerning pathophysiology 
of depression in PD patients has been accumulated from structural and func-
tional neuroimaging studies (Cardoso et al., 2009; Ring et al., 1994; Remy et 
al., 2005; Feldmann et al., 2008; Politis et al., 2010). High-resolution structural 
MRI studies have shown that PD patients with depression display abnormality 
in size of some areas, including the orbitofrontal gyrus, the superior temporal 
pole, and the mediodorsal thalamus, when compared with the patients with PD 
alone (Cardoso et al., 2009; Feldmann et al., 2008). In PD, the degeneration of 
dorsal raphe nuclei neurons occurs early. Functional neuroimaging techniques 
have also been used to study depression in PD patients (Cardoso et al., 2009; 
Ring et al., 1994). A PET study found decreased levels of regional cerebral 
blood flow (rCBF) in the medial prefrontal cortex and the cingulate cortex in 
depressed PD group, in contrast to the non-depressed PD group (Ring et al., 
1994). Using fMRI, Cardoso and his colleagues observed decreased activity in 
the left mediodorsal thalamic nucleus and the left dorsomedial prefrontal cortex 
of depressed PD patients, but not of non-depressed PD patients (Cardoso et al., 
2009). Depression in PD patients may thus be associated with abnormal altera-




Figure 3. Schematic depiction of connections between the prefrontal cortex and limbic 
structures within the limbic-cortico-striato-pallido-thalamic circuits related to the 
medial and orbital prefrontal cortex networks implicated in depression. A decrease in 
the inhibitory control of the limbic structures by the PFC is associated with cognitive, 
behavioural and other signs of depression as well as abnormalities in neuroendocrine 
function, pain modulation and neurotransmitter activity (affecting the raphe, seroto-
nergic nuclei and noradrenergic nucleus coeruleus), through its connections with the 
hypothalamus and the midbrain, in particular the periaqueductal area (adapted from 
Palazidou, 2012, with permission). 
 
 
In a systematic review of neuroimaging studies investigating symptoms of 
apathy, depression, and anxiety in PD, frontostriatal circuits were identified as a 
shared pathway in the pathogenesis of all three of these affective disorders 
(Wen et al., 2016). PET studies have shown hypometabolism in the caudate and 
orbital-inferior frontal lobe, reduced cortical 5-HT1A receptor binding and a 
reduction in dopaminergic and noradrenergic binding in the limbic system in 
PD patients with depression, compared to non-depressed PD patients (Chen & 
Cheng, 2008). The organic hypothesis of depression associated with PD may be 
explained by dysfunction in the following brain regions, neural networks, and 
neurotransmitters: (1) subcortical nuclei and the frontal lobes; (2) cortical-
striatal-thalamo-cortical and basal temporal limbic neural networks; and (3) 
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serotonergic, noradrenergic and dopaminergic neurotransmission mechanisms 
(Chen & Cheng, 2008). Previous research on the involvement of the seroto-
nergic system, particularly as assessed by methods incorporating transcranial 
sonography, has revealed that raphe echogenicity is reduced in depressed versus 
non-depressed PD patients (Becker et al, 1997; Berg et al., 1999).  
Postmortem studies (Kish, 2003) and in vivo neurochemical imaging investi-
gations (Albin et al., 2008; Guttman et al., 2007; Kerenyi et al., 2003) have sug-
gested that a brain serotonergic deficiency in PD could in part explain emotio-
nal and cognitive disturbances in PD patients (Boileau et al., 2008). Conversely, 
degenerative basal ganglia diseases and lesions of the striatum and orbitofrontal 
cortex increase the risk for developing major depressive episodes (Price & 
Drevets, 2010). Selective serotonin reuptake inhibitors, when chronically used 
to treat depression and anxiety, can induce motor side effects (tardive dyski-
nesia, parkinsonism, akathisia and dystonia) (Bilen et al., 2008; Leo, 1996). In 
vivo clinical studies have also revealed a relationship between non-motor 
symptoms and the dysfunction of the serotonergic system. In fact, PD patients 
receiving dopamine-rich grafts showed improvement in motor symptoms, but 
they still suffered from non-motor symptoms. In these patients, functional 
imaging showed that the dopaminergic neuron innervations were restored, but 
the serotonergic uptake binding was markedly reduced (Politis et al., 2012). 
Concurrence of depression and cognitive dysfunction are well known in a 
wide range of clinical populations, including PD patients (Chaudhuri & Scha-
pira, 2009; Marazziti et al., 2010). Neuroimaging studies provide further insight 
into the pathophysiology of this association in PD and indicate a crossroad, 
meaning a common pathway for depression and cognitive dysfunction. The 
mesocortical dopaminergic system facilitates working memory function via 
direct inputs to prefrontal cortex (Mattay et al., 2002). Neuropathologically, 
clinical changes in PD are mainly represented by dopaminergic neuronal loss 
occurring in the nigrostriatal tract and reduced dopamine projections to the 
striatum, which leads to inefficiencies in frontostriatal pathways (Jellinger, 
2001). The cardinal feature of PD is represented by the deterioration of mid-
brain dopamine neurons, including dopamine projection to the ACC (Vogt, 
2009; Thobois et al., 2010). 
Taken together, PD-related depression may be related to dysfunction in the 
subcortical nuclei and the prefrontal cortex, the striatal-thalamic-prefrontal 
cortex circuitry and the basotemporal limbic circuit, as well as the brainstem 
monoamine and indolamine (i.e. dopamine, serotonin, and norepinephrine) 
systems (Murai et al., 2001; Mentis et al., 2002; Mayberg, 2003; Feldmann et 
al., 2008; Weintraub et al., 2005a; Weintraub et al., 2005b; Cardoso et al., 2009; 
Hesse et al., 2009; Felicio et al., 2010; Walter et al., 2010). Discrete compo-
nents of frontostriatal pathways could generate individual differences in PD 
patientsʼ neuropsychiatric manifestations. Expanding knowledge on the imaging 
biomarkers of depression related to PD represents both scientific and practical 
significance. The following part of this dissertation contributes to this aim.  
 
29 
2.4. STUDY I: Prevalence of depressive symptoms and their 
association with brainstem raphe echogenicity in patients 
with Parkinsonʼs disease and non-PD controls 
The aim of Study I was twofold: to describe the prevalence and severity of 
depressive symptoms in PD, as well as to analyze possible associations between 
brainstem raphe (BR) echogenicity and depressive symptoms in an Estonian 
sample of patients with PD (n=266) compared to age- and education-matched 
healthy (non-PD) controls (n=168). Transcranial sonography (TCS) is a method 
for distinguishing certain pathological processes in the brain. Low echogenicity 
of the mesencephalic midline, more precisely the brainstem raphe, is a common 
finding in 50–70% of patients with unipolar depression (Becker et al., 1994, 
Walter et al., 2007a), is associated with responsiveness to serotonin-reuptake in-
hibitors (Walter et al., 2007b), and thought to reflect an alteration of the seroto-
nergic system. The first objective of the study was to confirm and elaborate on 
previous evidence whereby decreased echogenicity of the mesencephalic raphe 
had been demonstrated in 40–60% of patients with PD and depression (Becker 
et al., 1997, Walter et al., 2007a, Berg et al., 1999). Depression may in fact 
occur before the onset of motor symptoms, suggesting that in its early stages, 
the neuropathological process of PD itself increases the risk of depression 
(Schuurman et al., 2002; Leentjens et al., 2003, Reijnders et al., 2008).  
The results of Study I implicated that severely depressed patients (with or 
without PD) showed significant BR hypoechogenicity. In the PD group, 38.7% 
had mild and 35.7% had severe depressive symptoms, while in the control 
group, 26.8% had mild and 28.6% had severe depressive symptoms. The per-
centage of controls with depressive symptoms exceeding normal limits was 
significantly lower than in the PD group (p < 0.001). Higher depressive symp-
tom severity was associated with longer PD disease duration, more severe 
motor and cognitive impairment, and indicative of advanced disease stages.  
As for the studyʼs second objective to find possible associations between 
brainstem raphe echogenicity and the severity of depressive symptoms, it was 
found that BR echogenicity in both PD patients and non-PD controls was 
directly related to their total Beck Depression Inventory (BDI) score, although a 
significantly greater reduction of BR echogenicity in patients with PD and 
depressive symptoms was found compared to depressed non-PD controls. In the 
PD group, the direct relationship of depressive symptom severity and hypo-
echogenic BR remained significant even after accounting for age, disease 
duration, and Hoehn & Yahr stage – the level of affective disturbance directly 
reflected the anatomical changes in BR. Interestingly, 58.7% of controls with a 
normal BDI score showed partially reduced visibility of the BR. This number 
grew to 64.4% in a sub-sample of the control group with mild depressive 
symptoms. In the PD group, the respective percentages were 23.5 and 53.4. It 
was also noted that patients who were using antidepressants had significantly 
higher BDI scores than those who were not. 
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Study I, confirming that the prevalence of depressive symptoms in the patient 
sample was found to be significantly higher than in controls, demonstrated that 
depressive symptom severity is associated with the clinical aspects of PD. The 
findings were in concordance with previous reports whereby BR echogenicity 
was seen to be altered in individuals with depression (Becker et al., 1994, 
Walter et al., 2007b). The study underlined the growing importance and utility 
of brain-based biomarkers of depression in PD. Depression in PD patients is 
associated with abnormal alterations in the prefrontal-limbic network (Wen et 
al, 2013). Tying in to the notions that neuroanatomical alterations of the BR are 
involved in the pathogenesis of depressive disorders and a substantial number 
of depressed PD patients fail to respond to conventional antidepressive 
treatment, it was concluded that new – or additional – treatment methods to 
account for treatment-resistant depression in patients with a pronounced mono-




3. NON-INVASIVE BRAIN STIMULATION AND 
DEPRESSION RELATED TO PARKINSONʼS DISEASE  
3.1. Non-invasive brain stimulation:  
a brief overview of known mechanisms 
NIBS techniques include, among others, rTMS and tDCS. The rTMS method 
involves the application of a rapidly changing magnetic field in order to induce 
currents and action potentials in the underlying brain tissue. The tDCS involves 
the application of weak (1–2 mA) electrical currents to modulate neuronal 
membrane potential. This thesis will focus on the therapeutic applications of 
rTMS. 
Despite the wide use and clinical potential, the neurobiological mechanisms 
of action of NIBS methods at the whole-brain level are still relatively poorly 
known. Most of what we know about these mechanisms is derived from neuro-
physiological studies focusing on the motor system. (Walsh & Cowey, 2000; 
Hallett, 2007). The combination of NIBS with neuroimaging is a powerful tool 
to investigate the effects of stimulation (Ko et al., 2013). Transcranial magnetic 
stimulation (TMS) is an established neurophysiological tool to examine the 
integrity of the fast-conducting corticomotor pathways in a wide range of 
diseases associated with motor dysfunction (Groppa et al., 2012). Single-pulse 
TMS is easy to employ because it is noninvasive, non- painful and safe. It can 
probe the function of many different parts of the cerebral cortex, excite, inhibit 
and assess aspects of excitability (Hallett, 2000). Growth in the research and 
diagnostic application of TMS prompted the rise of experimental protocols 
(including rTMS) that were designed to alleviate various clinical symptoms 
(George et al., 1999; Kobayashi & Pascual-Leone, 2003; Rossini & Rossi, 
2007; Richards et al., 2008; Bhandari et al., 2016). rTMS can be used to excite 
(high-frequency rTMS) or inhibit (low-frequency rTMS) the underlying cortical 
tissue. The effects of rTMS propagate from the directly targeted cortical region 
to the connected nodes along neural networks (Eldaief et al., 2013; Shafi et al., 
2012). The distributed effects are considered crucial for the clinical efficacy of 
rTMS (Fox et al., 2014). Studies have demonstrated the propagation of the 
stimulation effects to connected brain regions (Bergmann et al., 2016; Hallett et 




Figure 4. (A) Visual illustration of the induction of electrical currents in the brain 
through the magnetic pulses (dashed lines) applied by means of the coil; (B) Examples 
of 10 s of rTMS at 1 Hz (first trace) and at 5 Hz (second trace); 1 s of rTMS at 10 Hz 
and an example of 20 Hz application (trains of 2 s interleaved by a pause of 28 s); (C) 
Image of the location of the (left) dorsolateral prefrontal cortex in the brain (Adapted 
from Spronk, Arns, and Fitzgerald, 2011, with permission). 
 
 
rTMS has been shown to modulate several neurotransmitter systems, increase 
neurotrophic factors, and induce changes on neuronal synapses via long-term 
potentiation (LTP) and long-term depression (LTD)-like mechanisms (Rektoro-
vá & Anderková, 2017; Rektorová & Biundo, 2019). 
The physiological aftereffects of NIBS depend, among other factors, on the 
stimulation protocols and on the precise coil type and placement, as well as on 
the current “state” of the brain, with a varying effect across subjects (Anderkova 
et al., 2015; Bergmann et al., 2016, Hallett et al., 2017). The behavioral after-
effects of rTMS may outlast the duration of multiple sessions of stimulation by 
weeks or months and thus may have therapeutic potential (Biundo et al., 2017). 
In general, rTMS may modulate the abnormal brain reorganization caused by 
distinct brain pathology and/or interact with the normal processes of brain 
plasticity such that it enhances compensatory mechanisms and leads to an 
increased brain reserve, thus potentiating brain resilience (Priori et al., 2009). 
Classic studies have shown that high-frequency rTMS (usually 5 Hz or higher) 
increases (Pascual-Leone et al., 1994) whereas low-frequency (1 Hz or lower) 
33 
rTMS (Chen et al., 1997) decreases corticospinal excitability. These findings 
led to a large number of studies that explored the use of rTMS as a form of 
therapeutic non-invasive neuromodulation in neurological and psychiatric dis-
orders. In these studies and interventions, some areas of the brain have turned 
out to be most promising targets for rTMS application. The DLPFC is regarded 
as most accessible for treatment with rTMS (Wassermann & Lisanby, 2001). In 
the following section, one of these areas − the DLPFC − will be focused upon, 
as it is one of the main brain areas of interest of this dissertation. 
 
 
3.2. The dorsolateral prefrontal cortex  
as a stimulation target 
The DLPFC is a key hub in the prefrontal-limbic network which connects to the 
orbitofrontal cortex, the thalamus, parts of the basal ganglia, the hippocampus, 
and primary and secondary association areas of the neocortex (Philip & Ulrich, 
2002). It has an important role in cognitive, executive and emotional processes, 
especially the downregulation of negative emotional conditions (Barbas, 2000; 
Davidson et al., 2002a; Pena-Gomez et al., 2011). Abnormal activity in the 
DLPFC may lead to a cognitive and mental disorder, and partly contribute to 
interest or pleasure deficiency and cognitive decline exhibited by patients with 
depression (Bench et al., 1992; Dragaševic et al., 2002). The “frontal asym-
metry hypothesis” of depression states that, in depression, there is an imbalance 
in left vs. right frontal brain activation (Henriques & Davidson, 1990). Early 
studies in the 1980s and early 1990s found a correlation between depression and 
hypoactivity in the left DLPFC, eventually leading to the selection of this 
region as a target for rTMS (George et al., 1994; Geroge et al., 1995). The 
converging evidence from lesion studies, stimulation studies, and connectivity 
studies backs correlative neuroimaging research in identifying the most central 
nodes of the brainʼs emotion-regulating networks (Downar & Daskalakis, 
2013). The DLPFC, the VMPFC and the rostral ACC are parts of the prefrontal-
limbic network which has been identified as being important for affective 
processing (Cardinal et al., 2002). Bennett (2011) identified that abnormal 
changes in the prefrontal-limbic network exist in patients with major depressive 
disorder. In addition, of the main brain regions known to be related to the 
pathophysiology of depression (e.g., prefrontal, cingulate, parietal, and temporal 
cortical regions, as well as parts of the striatum, thalamus, and hypothalamus), 
the DLPFC is regarded as one of the most accessible for treatment with rTMS 
(Wassermann & Lisanby, 2001). Similarly, DLPFC-targeted rTMS is one of the 
modes relatively more comfortable for the patient. The hypoactivity in the 
DLPFC in depression has been identified by a multitude of studies and regarded 
as a critical hallmark for depression, including PD-related depression (Bench et 
al., 1992; Ring et al., 1994; Dragaševic et al., 2002; Mottaghy et al., 2002; 
Fregni et al., 2006; Cardoso et al., 2008; Koenigs & Grafman, 2009). Similar 
results have been also found in depressed PD patients; a PET study reported a 
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decreased rCBF level in the DLPFC of depressed PD patients compared with 
non-depressed PD patients (Ring et al., 1994), and stimulating the DLPFC with 
rTMS can be effective in treating depression symptoms in PD (Dragaševic et 
al., 2002; Fregni et al., 2006). Together with these findings, it can be surmised 
that hypoactivation of the DLPFC may be an important factor for the genesis 
and development of depression in PD patients. A crucial variable to consider 
herein is laterality; in a study by Knoch et al. (2006) investigating the diffe-
rences between left/right DLPFC and low-/high-frequency rTMS, the authors 
demonstrated a clear effect of laterality – the left versus right dorsolateral PFC 
activated different networks, in support of prefrontal hemispheric asymmetry. 
The referred findings corroborate and complement the studies using different 
neuroimaging modalities, such as fMRI and EEG, demonstrating the pro-
pagation of the stimulation effects to connected brain regions (Bergmann et al., 
2016; Hallett et al., 2017). 
 
 
3.3. Non-invasive brain stimulation and clinical depression 
In recent decades, there has been increasing interest in treatment-resistant 
depression (TRD) (Berlim & Turecki, 2007b; Ruhe et al., 2012; Sackeim et al., 
2019). Earlier estimates suggested that two-thirds of patients in a major 
depressive episode have substantial improvement following their first antide-
pressant medication trial (Klein et al., 1980; Souery et al., 1999). The Se-
quenced Treatment Alternatives to Relieve Depression (STAR*D) study (Rush 
et al., 2004) challenged this perspective; in a large sample without a history of 
adequate antidepressant treatment failure in the current episode, approximately 
30% remitted following treatment with citalopram. Non-remitters received up to 
three additional trials of antidepressant treatment (Rush et al., 2006). The likeli-
hood of acute benefit decreased with each subsequent trial, and, if remission 
was obtained, the likelihood of relapse increased. For example, in STAR*D the 
probability of both remitting and sustaining that remission for a year was less 
than 5% in patients receiving their third antidepressant treatment (Conway et 
al., 2017). This prospective study and similar data (Fife et al., 2017; Mahlich et 
al., 2018; Rizvi et al., 2014; Saveanu et al., 2015; Thomas et al., 2013) have led 
to the estimate that approximately one-third of patients in a major depressive 
episode are characterized by TRD (Berlim & Turecki, 2007b; Cepeda et al., 
2018; Fava, 2003; Thase, 2011). TRD is associated with increased morbidity 
and mortality (Banankhah et al., 2015; Reutfors et al., 2018; Souery et al., 
2007), increased medical and psychiatric health care costs (Amos et al., 2018; 
Kubitz et al., 2013; Lepine et al., 2012; Mahlich et al., 2018; Olfson et al., 
2018; Russell et al., 2004), and markedly reduced quality of life (Johnston et al., 
2018; Mrazek et al., 2014). 
It has been 25 years since the first trials of rTMS for TRD showed marked 
improvement with high-frequency stimulation of the left DLPFC (George et al., 
1995; Pascual-Leone et al., 1996). Since then, dozens of trials have demons-
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trated a statistically significant improvement in depressive symptoms with 
active over sham rTMS. Newer studies identified significant limitations in the 
earlier trials and sought to address them (Daskalakis et al., 2008). This new 
generation of studies has steadily improved rTMS outcomes via stronger or 
accelerated dosing regimens, longer treatment courses, bilateral stimulation 
protocols, individually tailored stimulation frequencies, new coil geometries, 
more precise neuronavigation technologies, and more accurate TMS navigation 
methods than the traditional “5 cm rule” for locating the DLPFC (Downar & 
Daskalakis, 2013). With such improvements, many studies have consistently 
achieved rTMS remission and response rates of around 30–35% and 40–55%, 
respectively (Levkovitz et al., 2009; Holtzheimer et al., 2010; Li et al., 2010; 
Fitzgerald et al., 2011; McDonald et al., 2011; Blumberger et al., 2012). Several 
of these trials enrolled up to 200 patients, while making use of improved 
techniques such as bilateral stimulation or MRI-based neuronavigation. 
Although the use of sham controls in large trials is no longer universal given the 
well-established superiority of active over sham rTMS, the reported outcomes 
in these trials are more than 5-fold better than the ∼5% remission/∼10% 
response rates consistently seen for sham stimulation in this refractory popu-
lation (Lam et al., 2008). This near-doubling of rTMS efficacy represents a 
significant advance towards the viability of rTMS as a first-line treatment for 
refractory depression. In this population, rTMS remission rates now match or 
exceed the 23–33% remission rates seen for an open-label second medication 
trial or cognitive therapy in patients failing a first medication trial in the 
STAR*D study (Thase et al., 2007), or the 35% response and 22% remission 
rates seen for patients switching to psychotherapy after failing an antidepressant 
medication (Schatzberg et al., 2005). In 2014, HF-rTMS of the left DLPFC to 
treat depression received a recommendation corresponding to a Level A of 
evidence in the guidelines published by Lefaucheur et al (2014), further 
validated by updated guidelines in 2020 (Lefaucheur et al., 2020). Although 
rTMS therapy is nowadays applied worldwide in depressed patients, there is 
still a large heterogeneity in the published data concerning the populations 
included and the stimulation settings (Lefaucheur et al., 2020). The present 
recommendations are in favor of a definite antidepressant efficacy of HF-rTMS 
of the left DLPFC (using either a focal figure-of-8 coil or a deep H1-coil) and a 
probable antidepressant efficacy of LF-rTMS of the right DLPFC. They mostly 
apply to patients in an acute phase of a drug resistant MDD episode in the 
context of unipolar depression. Efficacy does not seem to differ significantly 




3.4. Non-invasive brain stimulation and  
Parkinsonʼs disease 
Available systematic reviews and meta-analyses have focused on rTMSʼ applic-
ability in alleviating the motor symptoms of various movement disorders, in-
cluding PD, and this has also been the main guiding principle upon selection of 
the stimulation target (mostly being M1 or SMA) (Arias-Carrión, 2008; Chou et 
al., 2015; Chung & Mak, 2016; Edwards et al., 2008; Fregni, 2005; Lefaucheur, 
2006; Lefaucheur, 2009; Wagle-Shukla et al., 2016; Zhu et al., 2015). rTMS has 
been shown to positively influence the motor aspects of PD, lessening tremor 
and dyskinesias to some extent (Mally & Stone, 1999). A systematic review and 
meta-analysis by Wagle Shukla and colleagues (2016) indicated that rTMS 
therapy in patients with PD results in mild to moderate motor improvements 
and has the potential to be used as an adjunct therapy for the treatment of motor 
dysfunction in PD. Recently published guidelines have given a recommendation 
of possible efficacy for the effect of high-frequency rTMS (5–25 Hz) of bila-
teral (multiple) M1 areas on motor symptoms of PD (Lefaucheur et al, 2020). A 
detailed analysis of rTMS as a therapeutic method in alleviating motor symp-
toms of PD is outside the scope of this dissertation and the reader is referred to 
the references indicated above. 
A recent review on the therapeutic use of rTMS have indicated probable 
antidepressant efficacy of HF-rTMS of the left DLPFC in PD patients (Level B) 
(Lefaucheur et al., 2020). As for the treatment of cognitive impairment in PD, 
there is no universal agreement on efficacy, on which stimulation protocols 
should be utilized, and for how long they should be applied. Only a few studies 
are available with preliminary results, and most concern depressed PD subjects 
(Rektorová & Anderková, 2017). Helmich and colleagues (2006) found that 
rTMS of the frontal cortex in order to regulate the dopamine system caused an 
increase in dopamine release in the basal ganglia which in turn improved the 
executive function of PD patients. Executive function, as a process of higher 
cognitive function, is usually closely related to the cooperation of multiple brain 
regions. It is feasible that stimulation of the DLPFC not only impacts cortical 
excitability directly within the stimulation area but also in the whole circuitry 
connected to it. A series of studies using PET have shown that short trains of 10 
Hz of rTMS can stimulate subcortical dopamine release in the striatum 
(specifically, the caudate nucleus and putamen) in both healthy subjects and PD 
patients (Fuggetta et al., 2020), providing further evidence that the associative 
basal ganglia-thalamo-cortical loop is interconnected with the stimulated area 
(Strafella et al., 2001; Siebner & Rothwell, 2003). 
As explained earlier in this dissertation, depression and cognitive dysfunc-
tion, specifically in the executive domain, might partially arise via dysfunctions 
of the same dopaminergic frontostriatal network. Depressive symptoms such as 
psychomotor slowing, concentration difficulties, and negative rumination may 
be explained by disruptions and malfunctioning of these projections. The de-
ficits in executive functions reflect the damage to the frontal lobes of the brain, 
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particularly the DLPFC, which ultimately leads to the degradation of the nigro-
striatal dopamine pathway and the midbrain pathway (Dalrymple-Alford et al., 
2011). Due to the similar localization of cognitive and affective neural 
pathways within or connected to the frontal cortex, rTMS of the DLPFC 
represents a valid opportunity to address multiple PD-related neuropsychiatric 
issues simultaneously. An optimal set of clinical guidelines to address both the 
emotional and cognitive problems in patients with PD and depression using 
rTMS with maximal efficiency and safety has yet to be agreed upon. For this 
purpose, and in addition to experimental studies, systematic analysis of what 
has been empirically found so far is recommendable. 
 
 
3.5. STUDY II: Repetitive transcranial magnetic stimulation 
of the dorsolateral prefrontal cortex to alleviate 
depression and cognitive impairment associated with 
Parkinsonʼs disease: a review and clinical implications 
While high-frequency rTMS to the left DLPFC is an approved treatment for 
medication-resistant depression in many countries, it is not approved for the 
treatment of other conditions. In many disorders such as PD, there are multiple 
small and medium sized studies but there are no large randomized controlled 
trials that are required for regulatory approval. Studies in the format of syste-
matic reviews are particularly useful to assess the available evidence in these 
conditions. 
The hypoactivity of the left DLPFC has been a critical hallmark in previous 
models of the pathophysiology of depression. Brain imaging studies in de-
pressed patients have consistently found abnormalities in the prefrontal cortex, 
cingulate gyrus, orbitofrontal cortex, or deeper limbic regions like the amyg-
dala, insula and hippocampus which are often reversible after clinical recovery 
(Fitzgerald et al., 2006a; Steele et al., 2007). Evidence in line with the “frontal 
asymmetry hypothesis” of depression has been demonstrated in rTMS studies 
incorporating functional brain imaging on PD patients with comorbid de-
pression (Fregni et al., 2006; Cardoso et al., 2008). rTMS of the DLPFC has 
been shown to exert antidepressant-like effects superior to placebo and equi-
valent to standard psychopharmacological treatment. 
The studyʼs objective was to pool available scientific literature on the thera-
peutic usage of rTMS on non-motor symptoms of Parkinsonʼs disease as-
sociated with the DLPFC (i.e. depression and cognitive impairment). The goal 
of the literature review was to obtain confirmation whether rTMS is an effective 
treatment method for emotional and cognitive problems associated with PD. 
127 initial records were retrieved. After the identification of relevant articles, 
screening and eligibility analysis, 23 articles fit the inclusion criteria. 10 RCTs 
and 3 open-label studies centered on depression, whereas 6 RCTs and 4 open-
label studies on cognition. Four of these included both mood and cognition pre- 
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and post-stimulation measures as outcomes. Nearly all studies included in the 
review that applied high-frequency rTMS over prefrontal brain regions found 
beneficial effects on mood, thereby alleviating depression associated with PD, 
insofar as evidence-based clinical recommendations, protocols and safety mea-
sures were applied.  
To summarize the results of the review of studies that included mood/de-
pression data from 314 subjects: presented here as a ready-to-use set of 
evidence-based clinical guidelines, rTMS using a f8-coil positioned on the left 
DLPFC, preferably with a stimulation frequency ranging between 1 and 15 Hz 
(i.e. high-frequency), with a treatment period of at least 2–4 weeks, will give a 
rapid therapeutic response comparable to an effective regimen of antidepres-
sants in a majority of patients with depression related to PD. In regard to PD-
related cognitive impairment, the results from rTMS studies were mixed, 




4. PERSONALIZING TREATMENT WITH REPETITIVE 
TRANSCRANIAL MAGNETIC STIMULATION 
4.1. Known factors affecting treatment course 
Previous studies have identified multiple factors, including female sex, older 
age, single status, education level, physical disease, family history of depres-
sion, cognitive disorders, smoking status, alcohol use, early childhood adver-
sity, certain personality traits, and recent positive and negative life events, that 
can affect the progression of depression in PD patients (Global Parkinsonʼs 
Disease Survey Steering Committee, 2002; Schrag, 2006; Reijnders et al., 2008; 
Leentjens et al., 2013). A study by Wichowicz and colleagues (2006) examined 
various clinical characteristics in association with depression in PD, and sug-
gested that the severity of PD is related to depression. Longer duration of 
illness, a younger age of PD onset, frequent falls, a history of anxiety and 
memory problems are also associated with an increased rate of depression 
(Dissanayaka et al., 2011). The contribution of mood to patient´s QoL in PD is 
a consistent finding in the literature, even in studies using different methodo-
logies (Karlsen et al., 1999; Schrag et al., 2001; Schrag, 2006; Santos-Garcia & 
de la Fuente-Fernández, 2013; Kadastik-Eerme et al., 2015). The magnitude of 
the effect of mood on QoL is greater for patients with longer disease duration 
(Santos-Garcia et al., 2020). Elderly subjects with late-onset depression show a 
higher prevalence of neuroimaging correlates of cerebrovascular disease rela-
tive both to age-matched healthy controls and to elderly patients with an early 
age at depression-onset (Drevets et al., 2008). The presence of pain has been 
found to be significantly associated with depression scores, even after adjusting 
for demographic and clinical variables (Ehrt et al., 2009). A recent study by 
Chang et al. (2020) found that depression in PD is strongly associated with 
anxiety and sleep disturbances, while the association with physical comorbidi-
ties was not significant.  
The behavioral effects of rTMS have been found to depend on the fre-
quency, intensity, and duration of stimulation (Padberg et al., 2002; Avery et 
al., 2006; Fitzgerald et al., 2006b; Fitzgerald et al., 2006c; OʼReardon et al., 
2007). The most important parameters that rTMS protocols in depression can be 
distinguished on are the stimulation frequency and the stimulation location. The 
stimulation frequency refers to the number of pulses delivered per second, as 
can be programmed on the TMS device. High-frequency (HF-)rTMS usually 
includes frequency parameters of 5 Hz or above, whilst low frequency (LF-
)rTMS incorporates stimulation frequencies of 1 Hz or below. In addition to 
studies applying solely HF-rTMS or LF-rTMS, combined approaches have been 
proposed. The excitatory HF-rTMS protocols are applied over the left DLPFC 
and inhibitory LF-rTMS protocols are applied over the right DLPFC. The choice 
of the stimulation frequency has been thus closely linked to the stimulation 
location (Spronk, Arns, & Fitzgerald, 2011). Consequently, when attempting to 
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treat PD-related depression by NIBS methods, right DLPFC excitability is 
advised to be suppressed and left DLPFC to be facilitated. 
While rTMS treatment has been used with growing frequency over recent 
decades, its mechanisms and effects are still far from being transparent and 
unanimously recognized. Consequently, there are gaps in our knowledge and in 
the practices used. Multiple prior treatment failures are associated with reduced 
rates of response to subsequent depression treatment, including with rTMS; 
comparison of remission rates based on prior pharmacotherapy using data from 
the THREE-D trial (Blumberger et al., 2018) showed that three or more treat-
ment failures may be associated with lower remission rates with rTMS (Hsu et 
al., 2019). Studies investigating rTMS effects on TRD associated with PD are 
scarce. A meta-analysis by Lesenskyj and colleagues (2018) qualitatively and 
quantitatively evaluated the use of rTMS for the treatment of refractory depres-
sion in patients with PD. Six of the 7 studies meeting inclusion criteria of the 
study reported significantly improved depression scores, large effect sizes, and 
significant p-values. When all study groups that applied rTMS to the DLPFC 
were considered together and weighted based on sample size, the effect size 
(1.37) suggested a notable reduction in depression following rTMS. However, 
the authors acknowledge that the findings reported in their meta-analysis could 
be a result of placebo and suggest rigorous control for possible placebo effects 
in planning future studies. 
Taken together, an increasing amount of evidence is showing the therapeutic 
effects of rTMS on PD-related non-motor functions neuroanatomically linked to 
the DLPFC. However, the results vary, which presents a need for the refinement 
of possible stimulation parameters applicable to clinically heterogeneous patient 
sub-populations such as those with treatment-resistant depression and other 
neuropsychiatric comorbidities of the PD-related neurodegenerative process. 
 
 
4.2. STUDY III: High-frequency repetitive transcranial  
magnetic stimulation to the left dorsolateral prefrontal cortex 
of patients with Parkinsonʼs disease and treatment-resistant 
depression: a pilot study 
It has been shown that 50–60% of PD patients do not achieve an adequate thera-
peutic response following a standard course of antidepressants (Fava, 2003). 
Even with a combination of psychotherapy, more than 30% of depressed 
patients are resistant to antidepressant treatment (Fekadu et al., 2009; Rush, 
2007; Weintraub et al., 2005a). Advanced stage multimorbid PD patients with 
polypharmacy represent a relevant challenge for therapeutic safety (Chen & 
Cheng, 2008). As indicated earlier in the dissertation, rTMS has been shown to 
be an effective treatment option for major depressive disorder. There is less 
evidence on mood benefits associated with targeted rTMS use in patients with 
depression associated with PD, including those who are resistant to anti-
depressant treatment. Some studies have confirmed that high-frequency rTMS 
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(5–20 Hz) delivered to the left DLPFC for 2–4 weeks is able to produce potent 
antidepressant, anxiolytic and cognitive effects in PD patients while being 
functionally equivalent to pharmacological treatment with fluoxetine (Boggio et 
al., 2005; Fregni, 2004; Fregni et al., 2006). Other studies have indicated a 
moderately positive change after rTMS in the context of both treatment-naive 
depression and TRD associated with PD (Cardoso et al., 2008; Epstein et al., 
2007; Pal et al., 2010). In a few instances, alleviation of cognitive dysfunction 
in addition to the mood disorder has also been observed when rTMS is applied 
to the left DLPFC (Lefaucheur, 2009). No specific guidelines were found for 
using rTMS to treat treatment-resistant depression in PD patients. Studies are 
still needed to clarify the effects of rTMS on rates of TRD in the context of PD.  
The main objective of this prospective pilot study was to establish a 
preliminary effective, safe and tolerable rTMS protocol for PD patients with 
TRD, i.e., those who do not neatly fit within the available stimulation guidelines 
(Lefaucheur et al., 2014; Lefaucheur et al., 2020; Rossi et al., 2009; Rossini et 
al., 2015). Six PD patients [3m/3f, mean age of 61.3 yrs (SD = 11.89, range 42–
76), mean education level of 13.2 yrs (SD = 2.86), and a mean PD duration of 
5.2 yrs (SD = 1.72, range 3–7)] with TRD were treated with a regimen of high-
frequency (10 Hz) rTMS targeted at the left DLPFC. The treatment was carried 
out in the amount of 500 impulses per stimulation session, two sessions per 
week for a period of six consecutive weeks, amounting to a total of 6000 im-
pulses in 12 sessions. The individual effects of rTMS on motor function, mood 
and cognition were studied simultaneously in patients with both PD and TRD, 
also taking note of the possible functional impact on the level of everyday 
independence and quality of life. It is well known that the variability in coil 
placement can have a large impact on the biological effects, for example as 
demonstrated by stimulation site connectivity and clinical efficacy of rTMS in 
major depression by Fox and colleagues (2012). From an anatomical point of 
view, the most accurate method for targeting the DLPFC should be to use 
individual MRI data and a neuronavigation system, as suggested by several 
neuroimaging studies (Fox et al. 2012; Luber et al., 2017; Dubin et al., 2017). 
Consequently, in this study, a navigated rTMS system was chosen to be used in 
order to achieve maximal neuroanatomical precision. The subjects were care-
fully monitored for any possible change in various physical and psychological 
domains – both at fixed intervals of assessment and during individual stimu-
lation sessions. Due to the clinically complex characteristics of the subject 
sample and lack of specific stimulation guidelines, the authors focused on 
individual scores and case reports rather than relying on group comparisons. 
In the present study, there was a downward trend observed for individual 
BDI scores in all subjects apart from one individual. A non-deleterious effect of 
rTMS on most individual cognitive tasks and a short-term beneficial effect on 
self-reported cognitive functioning was found, although the latter had returned 
to baseline at the last assessment phase. The effects of rTMS were particularly 
evident in specific cases, which again stresses the interindividual variability in 
both clinical status and characteristics of treatment resistance. Diligent assess-
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ment of key individual characteristics of the participants for prescribing specific 
rTMS protocols and delineating phenotype-dependent limitations of the prac-
tical usage of rTMS are important aspects of subsequent research. The impact 
of brain stimulation was directly related to the personʼs level of everyday 
independence and quality of life insofar as a distinctly alleviating effect on 
individual measures was observed. It is clear that some subjects possibly gained 
more, whereas in others, the intervention had little or no benefit. The few sub-
jects with a clearly observed treatment response had high levels of anxiety, so 
the alleviation in mood problems may directly reflect the possible anxiolytic 
properties of rTMS treatment. Depressive symptoms may be part of an under-
lying anxiety disorder which would therefore be a direct representation of 
depression in PD being qualitatively different from “pure” major depressive 
disorder (Akhmadeeva et al., 2018). 
Considering the modest number of subjects and many possible combinations 
of independent variables within repeated assessments, the dependent variables 
did not show a clear pattern of change, although possible trends emerged (e.g., 
in affective measures, as described above). While highlighting the large 
variability, the results of this prospective pilot study provided the basis for 
developing an extended treatment protocol, pending validation with a larger 
sample. The extent of possible beneficial effects as well as further exploration 
of risks and unforeseeable adverse effects in working with this highly specific 
and vulnerable segment of PD patients can thus become evident early on. 
 
 
4.3. Future perspectives 
There are a multitude of concepts, factors, and methods to consider in treating 
neuropsychiatric problems associated with PD that the research activities done 
within the scope of this thesis have implicated. A very recent critical review by 
Dhingra and colleagues (2021) outlined the clinical manifestation and treatment 
possibilities of neuropsychiatric symptoms including anxiety, depression, 
psychosis, impulse control problems, disordered sleep, and cognitive dysfunc-
tion, emphasizing their unique presentation in patients with PD. While only a 
part of them fit within the boundaries of this dissertation, they warrant con-
sideration in further clinical studies looking to treat neuropsychiatric problems 
in PD. A brief and selective overview is presented below. 
 
Anxiety 
Compared to depression, anxiety in PD has received far less attention, which is 
somewhat surprising given that anxiety can be both mentally and physically 
disabling at times, particularly when frequent anxiety or panic attacks occur 
(Chang et al, 2020). Anxiety is indeed a common non-motor symptom in PD, 
with a prevalence of 25% to 49% (Pontone et al., 2009; Dissanayaka et al., 
2010). The increase in the level of anxiety and the number of discrete anxiety 
attacks have been associated with non-motor fluctuations, particularly occurring 
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with the onset of “off” periods or at certain times of day (e.g., late afternoon or 
early evening) (Pontone et al., 2009; Dissanayaka et al., 2010). Similar to 
depression, an increased frequency of anxiety disorders can be observed up to 
20 years prior to PD onset (Gonera et al., 1997; Shiba et al., 2000), but other 
than this finding − suggesting a contributing role for disease-related effects on 
brain monoaminergic nuclei in prodromal PD − not much is known about the 
etiology of anxiety in PD. It is known that 14% to 40% of PD patients are 
diagnosed with anxiety comorbid with depression (Schrag, 2004; Dissanayaka 
et al., 2010). Both anxiety and depression have been observed to induce similar 
changes in norepinephrine and serotonin systems; anxiety disorders may occur 
earlier than depression, and even before motor symptoms appear in PD. This 
progression may explain the occurrence of depression and anxiety in PD during 
the premotor phase (Weintraub et al., 2020). Given possible adverse effects 
associated with benzodiazepine use in PD, it is pertinent to consider non-
pharmacological treatment approaches such as NIBS and CBT. At the same 
time, it is also important to consider other PD-related NPS such as psychosis, 
impulse control disorders and apathy. As acute anxiety episodes include diffi-
culties of state control, NIBS protocols known to affect prefrontal control 
centers (e.g., right DLPFC) might also be viable direction of future research. 
 
Young-onset PD 
Study III of this dissertation included patients aged under 50 years. Young 
Onset Parkinsonʼs disease (YOPD) occurs in people younger than 50 years of 
age. Most people with idiopathic, or typical, PD develop symptoms at 50 years 
of age or older (i.e. Late Onset Parkinsonʼs disease, LOPD). Young adults are 
more likely to be employed and have younger children and, therefore, the 
impact on overall productivity and prognosis is greater for YOPD than LOPD 
(Calne & Kumar, 2008). Because YOPD patients also have longer disease 
duration by the time they reach the age of the LOPD patients (Schrag et al., 
1998), they may suffer from more physical, economic, and psychological 
consequences. Non-motor features of PD seem to have a particularly distressing 
impact on HR-QoL of patients with YOPD (Mehanna & Jankovic, 2009). Im-
pulse control disorders, such as gambling, compulsive shopping, and sexual 
addiction were reported with a nearly threefold increase in those taking dopa-
mine agonists (often a preferred class of anti-PD drugs in YOPD) and a 50% 
increase associated with levodopa treatment (Voon et al., 2006). Dopamine 
dysregulation syndrome has been also associated with YOPD, especially in 
males (Barbosa et al., 2018). Although YOPD patients have a lower risk for 
dementia (Chaudhary et al., 2018), several studies have found that YOPD 
patients had a higher rate of depression and restless legs syndrome as well as 
sexual dysfunction than their older counterparts; for a review of these studies, 
please refer to the review by Mehanna and Jankovic (2019). Because of the 
above-mentioned undesirable side effects of dopaminergic treatment, NIBS 
may be preferred in cases where it holds the greatest potential of sufficient 
efficacy. 
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New developments in using rTMS 
There has been an increasing interest in exploring the use of rTMS treatment 
protocols (including their accelerated versions) in recent years, as well as an 
increase in studies exploring the therapeutic benefits of theta-burst stimulation 
(TBS); a recently published direct parallel groups comparison by Fitzgerald and 
colleagues (2020) showed that an intermittent TBS (iTBS) protocol may be 
used to achieve similar therapeutic benefits as those obtained with a standard 
daily rTMS treatment schedule. In the study, iTBS produced similar clinical 
benefits to standard rTMS in terms of depression ratings, quality of life, and 
assessments of suicidality without the occurrence of any serious adverse events. 
An increased rate of treatment-emergent side effects or observable cognitive 
impairment was not observed. The THREE-D study demonstrated that iTBS is a 
non-inferior treatment compared to 10 Hz rTMS in patients with TRD (Blum-
berger et al., 2018). Based on an another studyʼs (Trung et al., 2019) results, 
there is indication of a potential therapeutic effect of multiple-session iTBS on 
PD-MCI that is likely mediated by improved visuospatial functions. 
NIBS approaches mostly target superficial cortical regions. One of the 
central challenges in NIBS research is how to achieve stimulation of deep brain 
regions when desired, because the electromagnetic fields applied during NIBS 
fall off in both intensity and focality with increasing depth (Bikson & Dmo-
chowski, 2019). The superficial cortex has many regions directly implicated in 
cognition and behavior, as well as participating in brain-wide networks (Faber 
et al., 2012, Vaseghi et al., 2015, Cabib et al., 2016, Ironside et al., 2019). 
Nevertheless, some brain regions strongly implicated in neurological and 
psychiatric disorders are subcortical, for example the subthalamic nucleus in PD 
(Rodriguez-Oroz et al., 2000, Gunalan et al., 2018) or subcallosal cingulate for 
TRD (Lujan et al., 2013, Holtzheimer et al., 2017). Consequently, the ability to 
effectively stimulate deep brain regions with NIBS would open new avenues for 
treating brain disorders and cognitive and behavioral manipulation (Dmo-
chowski & Bikson, 2017). This consideration is indirectly supported by the 
notion that traditional PD treatment has especially targeted subcortical struc-
tures, both with surgical approaches and medication. 
As rTMS also has the potential to alleviate motor symptoms in PD, it is a 
valuable treatment method to consider. The rTMS guidelines based upon the 
available evidence are available for future studies (Lefaucheur et al., 2020). For 
example, a recent study found that high-frequency rTMS over the supple-
mentary motor area (SMA) may be beneficial as an add-on therapy for 
alleviating freezing of gait in PD patients (Mi et al., 2019). 
 
Transcranial direct current stimulation in PD 
Transcranial direct current stimulation (tDCS) is a non-invasive neuromodu-
latory technique that may help treat various neurological and psychiatric dis-
orders (Fregni et al., 2021). It is administered via a constant electric current 
produced by a battery-operated current generator connected to at least two 
electrodes (anode and cathode) applied to specific head locations (or extra-
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cephalic regions in case of the return electrodes). Earlier results support the idea 
that active stimulation of the DLPFC with tDCS could have beneficial, lasting 
effects on both affective and cognitive domains in patients with PD (Boggio et 
al., 2006; Doruk et al., 2014; Broeder et al., 2015). Positive effects of combined 
cognitive training and tDCS have been shown in cognitively impaired PD 
patients (Manenti et al., 2018). As per the newest guidelines of tDCS usage in 
neurological and psychiatric disorders (Fregni et al., 2021), anodal DLPFC 
tDCS, being a functional analogue of the facilitatory rTMS protocol, is probab-
ly effective for cognitive function in PD (Level B evidence). In regard to motor 
function in PD, anodal motor/premotor/SMA tDCS is possibly effective (Level 
C), whereas anodal prefrontal tDCS is probably not (Level B). tDCS-based 
home treatment could be a viable treatment option (Dobbs et al., 2018; Cucca et 
al., 2019), especially during viral pandemics and the need for self-quarantine, 
when face-to-face meetings and in-house medical procedures are not feasible. 
 
Biomarkers of treatment response in clinical depression 
Major depression is currently defined based on clinical criteria and encom-
passes a heterogeneous mix of neurobiological phenotypes (Drysdale et al., 
2017). Only a few studies have focused on predicting outcomes following non-
pharmacological treatment (Bailey et al., 2019). Knowledge of such predictors 
may allow clinicians to elucidate the sources of inter-individual variability in 
NIBS responses and provide more tailored therapeutic intervention (Rektorová 
& Biundo, 2019). For example, according to Iseger and colleagues (2019), 
autonomic functioning variables such as heart rate (HR) and heart rate variabi-
lity (HRV) could serve as a potential target engagement mechanisms for opti-
mizing and individualizing NIBS treatments in depression; the authors have 
emphasized the importance of including HR and HRV measurements during 
human depression studies, in particular those that conduct NIBS, to investigate 
to a better extent the acute effects of NIBS on autonomic functioning, and to 
establish the efficacy of electrocardiogram (ECG) metrics in target engagement 
of the frontal-vagal network. Depression in PD has also been suggested to relate 
to significant alterations in the composition of gastrointestinal microbiome 
profiles, likely resulting from imbalances of gut and central nervous system 
neurotransmitters (Dinan & Cryan, 2017; Lubomski et al., 2020). 
Neuroimaging and neurophysiology can be utilized as readouts of neural 
changes induced by NIBS (Sverak et al., 2018). Online monitoring of the state 
of the brain has been suggested by several authors (Bergmann et al., 2016). The 
objective is to optimally tailor the NIBS treatment to meet the specific needs of 
individual patients. In an exploratory study by Avissar and colleagues (2017), 
TRD was marked by hypoconnectivity of executive and rostral motor front-
ostriatal pathways, but normal connectivity of limbic and caudal motor front-
ostriatal pathways. Higher baseline functional connectivity of the left DLPFC to 
the executive division of the striatum in depressed patients correlated with 
treatment response to TMS over the left DLPFC, suggesting that an intact 
pathway from the part of the cortex that is proximal to the stimulation site to 
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deeper structures may facilitate antidepressant effects. This raises the possibility 
that baseline functional connectivity could be used as a biomarker for treatment 
response to rTMS in clinical depression (Oliveira-Maia et al., 2017). 
Resting-state EEG (rsEEG) may be able to identify treatment-predictive 
heterogeneity in depression. A recent study (Wu et al, 2020) using rsEEG and 
machine learning sought to identify a neurobiological signature of response to 
antidepressant treatment as compared to placebo. The authors developed a 
rsEEG-optimized latent-space computation model that was capable to robustly 
predict treatment outcome with the antidepressant sertraline and distinguish 
between response to sertraline versus placebo at the individual patient level and 
which may furthermore support treatment selection between medication and 
rTMS. These findings lay a path toward machine-learning-driven personalized 
approaches to treatment in depression, grounded in individual-level neuro-
biology. 
Finally, as individual differences in resilience against and vulnerability to 
neurological disorders also depend on genetic variants based endophenotypes, 
fine-tuning individual NIBS protocols can be supported by the resuts of SNP 
genotyping. For example, association of depression and BDNF endophenotypes 
is well-established (Duman et al., 2021), substantiating NIBS-related research 
(Bocchio-Chiavetto et al., 2008; Cheeran et al., 2008; Krstic et al., 2014; Chan 
& Bota, 2019). It is not clear, however, whether the NIBS effects accrue as 
mediated by the motor areas or whether higher cognitive functions may also be 
involeved. A study by Tulviste and collegues (2019) showed that the BDNF 
genotype is associated with a bias in non-veridical preferences, and that Val/Val 
and Val/Met subjects responded differently to right DLPFC rTMS stimulation, 
further enhancing their preexisting selection biases. Thus, it is possible that 
genetic variance dependent efficacy of NIBS may be moderated by style of 
cognitive preferences and sensitivity to environmental cues. The latter is an 
important factor in the development of depression. Treatment resistance has 
been linked to insufficient brain plasticity and chronic inflammation; in a study 
encompassing the analysis of neurotrophic and inflammatory factors in 
psychiatric patients undergoing rTMS and ECT in order to refine the selection 
of patients and predict clinical outcomes, Valiuliene and colleagues (2021) 
showed that depressive patient treatment with rTMS had increased BDNF con-
centration, while a lower initial pro-inflammatory cytokine tumor necrosis 
factor alpha (TNFα) concentration could be a marker for treatment success in 
depressed patients undergoing rTMS. Future research in the domain of com-
bined utilization of NIBS and genotyping should help shed more light on the 
theoretical standing of the organic versus reactive hypothesis on the causes of 





5. GENERAL SUMMARY AND CONCLUDING REMARKS 
5.1. General summary 
The research questions posed at the beginning of this thesis were: 
 1. What is the current understanding of the neural circuitry of affective pro-
cessing in depression related to PD? 
2.  How does depression influence the overall disease trajectory and quality of 
life of PD patients? 
3.  Can a NIBS method such as rTMS effectively, safely, and tolerably be 
applied to treat depression related to PD? In addition to treating depression, 
is there evidence regarding the treatment of other common neuropsychiatric 
problems associated with PD using rTMS? 
4.  What are the known obstacles and emerging questions to be mindful of when 
using rTMS to treat PD patients with treatment-resistant depression? How 
can the treatment process be optimized to achieve better outcomes? 
The thesis summarized and expanded the knowledge and expertise regarding 
the therapeutic use of rTMS to treat depression related to PD, while also 
looking at possible implications for other neuropsychiatric symptoms and the 
patientsʼ health-related quality of life. To summarize the theoretical analysis-
based and empirical findings of the three studies included in this dissertation, 
the following statements can be made: 
 1. Depressive symptom severity is an important factor modulating various 
clinical aspects of PD, and quality of life of PD patients, tying into the notion 
that neuroanatomical alterations of the brainstem raphe nuclei are involved in 
the pathogenesis of depressive disorders and underlining the growing impor-
tance and utility of brain-based biomarkers of depression in PD. 
 2. It is likely that treatment with rTMS, adhering to an evidence-based selection 
of stimulation parameters, can give a rapid therapeutic response comparable 
to an effective regimen of antidepressants in a majority of patients with 
depression related to PD. Targeting the DLPFC by rTMS is a viable treat-
ment strategy for depression related to PD, and possibly other associated 
neuropsychiatric phenomena (e.g. cognitive impairment, anxiety, apathy), 
the latter pending on further research.  
 3. Patients with PD-related TRD represent a heterogeneous clinical sample with 
many complex, often inadequately met needs, emphasizing the interindivi-
dual variability in both clinical status and characteristics of treatment res-
ponse, thus warranting personalized intervention approaches that also include 
NIBS. 
Prospective, longitudinal studies have demonstrated that the cumulative pre-
valence of most psychiatric complications related to PD is higher than earlier 
cross-sectional studies suggested, with many disorders having a cumulative 
frequency over 50%, often beginning as early as the prodromal or de novo state 
(Chaudhuri et al., 2020). As summarized by Weintraub (2020), the neural 
substrate of NMS in PD is a complex interaction of PD pathology, treatment 
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effects, changes in multiple neurotransmitter systems and neural circuitry, and 
genetic influences. Non-motor complications related to PD are associated with 
excess disability, worse quality of life, poorer outcomes (including morbidity 
and mortality), and greater caregiver burden. Current treatment options for 
NMS in PD remain quite limited in their potentially beneficial effect. For 
multiple major neuropsychiatric disorders (e.g., depression, cognitive impair-
ment, and psychosis), there remains evidence for under-recognition and under-
treatment (Shulman et al., 2002; Chaudhuri et al., 2020). PD and its comorbi-
dities are no different in this respect. 
There is no consensus as to whether the etiology of depression associated 
with PD is organic, reactive, or both (Leentjens, 2004). There is a greater dege-
neration of dopaminergic neurons in the ventral mesencephalon in PD patients 
who are depressed than in those who are not (Mann & Kapur, 1995). Although 
levodopa is helpful in treating depression in a minority of PD patients, most do 
not exhibit a brisk response to this therapy alone. Depression is linked to 
changes in the activity of various neurotransmitters, including serotonin. As 
indicated in the results of Study I of this dissertation, serotonergic projections 
from the brainstem raphe nuclei undergo degeneration in PD, which may be a 
key abnormality in the etiology of depression associated with PD (Okun & 
Watts, 2002). Structural brainstem midline alterations have also been detected 
in both magnetic resonance images and transcranial sonograms in patients with 
primary depression and in those with depression associated with PD, supporting 
an important role of the median raphe nuclei in mood disorders (Berg et al., 
2001; Toomsoo et al., 2017).  
Depression is a long-term, relapsing condition with a tendency towards 
chronicity. Unfortunately, many patients do not achieve full remission for 
various reasons which include poor compliance, premature ending of treatment, 
the use of inadequate treatment options, and other factors. Despite the sub-
stantial number on studies on PD-related depression, its precise role in PD and 
respective treatment methods are insufficiently understood and underdeveloped. 
Repetitive transcranial magnetic stimulation is an established way to non-
invasively modulate brain excitability and to induce brain plasticity. However, 
studies incorporating rTMS to alleviate neuropsychiatric symptoms associated 
with PD are quite scarce. The precise combination of stimulation parameters 
suitable for depressed PD patients was up until recently yet to be determined. 
Study II set out to pool the available scientific literature on the therapeutic 
usage of rTMS on neuropsychiatric symptoms of PD specifically associated 
with the dorsolateral prefrontal cortex (i.e., depression and cognitive impair-
ment). The goal was to gain practical knowledge on using rTMS in the context 
of common neuropsychiatric symptoms of PD. One of the critical implications 
drawn out of this line of research is that the treatment outcome in NIBS depends 
on multiple factors, and the interactions between them. 
Previous studies have identified multiple factors, including female sex, older 
age, single status, education level, physical disease, family history of depres-
sion, cognitive disorders, smoking status, alcohol use, early childhood 
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adversity, personality traits, and recent positive and negative life events, that 
can affect the progression of depression in PD patients (Global Parkinsonʼs 
Disease Survey Steering Committee, 2002; Schrag, 2006; Reijnders et al., 2008; 
Leentjens et al., 2013). A recent meta-analysis indicated that the 5-HTTLPR 
genotype (S/S-Allele) is correlated with an increased depression risk in PD, and 
this highlights the needs for these people to take effective approaches in pre-
vention of depression of PD before its onset (Cheng et al., 2020). Study III 
provided preliminary evidence on applying rTMS that could suit clinically 
complex PD patients, i.e., those with treatment-resistant depression and/or other 
neuropsychiatric and somatic comorbidities. As implicated by the aforemen-
tioned study, difficulties concerning subject recruitment, strict inclusion criteria, 
difficulties complying to the study protocol, natural fluctuations in the disease 
course as well as patientsʼ motor and ADL difficulties along with the overall 
burden of the disease illustrate the challenges of conducting clinical research on 
subjects with advanced PD and comorbid neuropsychiatric and somatic 
problems. 
The identification of the factors related to the development and course of 
depression in PD patients could aid in the identification of preventive measures 
for this condition (Sagna et al., 2014). This dissertation has contributed to iden-
tifying influential factors and distilling optimal brain stimulation parameters for 
improving the treatment efficacy of PD-related depression, while argumentati-
vely proposing an approach that synthesizes the newest clinical evidence with 
traditional practices of applying NIBS. Many clinical trials applying rTMS have 
taken place in an inpatient setting, where treatments can be administered in con-
secutive days while maintaining the highest possible quality of life, thus 
minimizing subject attrition. While a robust clinical improvement is sometimes 
difficult to accomplish, the increase in HR-QoL metrics has been noted with 
growing frequency. This raises the need to keep incorporating measures on HR-
QoL into clinical studies that seek to treat neuropsychiatric symptoms related to 
neurodegeneration using NIBS methods. An empirical investigation illustrating 
this was done in Study III. Large-scale, innovative, neuroscience-informed 
protocols are recommended to elucidate the potential utility of rTMS for the 
complex neuropsychiatric symptoms associated with PD. Stimulating multiple 
targets on various cortical layers, varying stimulation techniques and protocols, 
as well as combining NIBS with cognitive training and other pharmacological 
and non-pharmacological interventions warrant further investigation in future 




5.2. Concluding remarks 
The research carried out during the proceedings of this dissertation has un-
earthed a multifaceted and complex system of interacting symptoms, comorbi-
dity ranges, and treatment pathways, also bringing forward various outstanding 
issues that challenge developing safe, efficient, and tolerable neuromodulation 
interventions for depression and related neuropsychiatric phenomena in PD. It 
has also further stressed the growing importance of personalized medicine. The 
etiology of the neuropsychiatric manifestations of PD is complex, and there is 
evidence to support multiple influential factors, including the psychological 
reaction to a serious, progressive diagnosis, a consequence of treatment of the 
disease, and the pathological process of PD (Dhingra et al., 2021). Problems 
with managing PD-related NPS include the need for early recognition, timely 
assessment and diagnosis using suitable measures, personalized planning of 
interventions (while being mindful of treatment resistance), and challenges 
related to maintaining the highest possible HR-QoL during the disease course. 
Refining, unifying and streamlining treatment protocols (including those 
applying NIBS) in both typical and more complex cases of PD is important to 
maximize the beneficial response and overcome treatment resistance whenever 
possible. Combining various treatment methods to achieve maximal success is 
both realistic and crucial to consider. Thankfully, the brain stimulation revo-
lution is unfolding around us as we speak. This area is fertile, expanding, and 
accelerating. Each month, we have novel brain stimulation methods obtaining 
clinical approval and improving societyʼs health by treating our diseases. The 
brain stimulation methods are not only powerful therapies, they are also in the 
midst of unlocking one of the last great frontiers in science – how the human 
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SUMMARY IN ESTONIAN 
Parkinsoni tõbi ja depressioon:  
ajumehhanismid ja mitteinvasiivse ajustimulatsiooni  
põhised ravistrateegiad 
 
Parkinsoni tõbi (PT) on teine kõige sagedamini esinev neurodegeneratiivne 
haigus, mis puudutab 2–3% üle 65-aastaseid inimesi (Poewe et al., 2017). 
Neuroloogilised haigused on nüüdseks kujunenud juhtivaks puudeallikaks maa-
ilmas, mille puhul Parkinsoni tõvele omistatud kasvu hinnatakse kiireimaks. 
PT-d iseloomustavad motoorsed ja mittemotoorsed tunnused, viimaste hulka 
kuuluvad ka neuropsühhiaatrilised häired. Neuropsühhiaatrilised sümptomid 
(näiteks emotsionaalsed, käitumuslikud ja kognitiivsed probleemid) on PT 
kontekstis olulised mittemotoorsed tunnused, mis esinevad sageli ja millel on 
märkimisväärselt pärssiv mõju inimese elukvaliteedile. Depressioon on väga 
levinud neuropsühhiaatriline häire, mille eluaegne haigestumisrisk on ligi 20% 
ning mida seostatakse kõrgenenud suremusega (Palazidou, 2012). Uuringud on 
näidanud üldpopulatsiooniga võrreldes depressiooni suurenenud levikut PT-ga 
inimestel − raskete depressioonivormide esinemissagedus on nende puhul 5–
20%, kusjuures kergemaid vorme esineb täiendavalt 10–30% PT-ga inimestest 
(Weintraub & Burn, 2011). Üle maailma esineb seega kuni pooltel PT patsien-
tidest kliiniliselt olulisi depressioonisümptomeid, mis on levimuse poolest 
tunduvalt kõrgem tase kui üldpopulatsioonis (13,5%)(Beekman et al., 1999; 
Hely jt., 2005; Dissanayaka jt., 2011; Marsh, 2013; Pachana jt., 2013). Depres-
sioon on PT-ga inimeste tervisega seotud elukvaliteedi (ingl. k. health-related 
quality of life) peamine mõjutegur (Jones jt., 2015), mis on ühtlasi seotud 
motoorsete ja kognitiivsete funktsioonide kiirenenud häirumisega (Ng jt., 2015; 
Santangelo jt., 2009). Longituuduuringud on näidanud, et depressioon on oma 
olemuselt pikaajaline ja episoodiline haigus, millel on kalduvus kroonilisusele 
ning kordumise oht suureneb iga uue episoodiga (Palazidou, 2012). Kolm 
neljandikku depressiooniga inimestest kogeb rohkem kui ühte depressiooni-
episoodi ning kordumise oht on suurem, kui esimene episood esineb nooremas 
eas ning kui depressiooni on esinenud ka teistel perekonnas (Hollon jt., 2006). 
Lisaks episoodide arvule mõjutab depressiooni prognoosi ka ravimata jäänud 
haiguse kestus; mida pikemaks see venib, seda halvem on võimalik ravivastus 
ja väiksem on remissiooni saavutamise tõenäosus (Okuda jt., 2010). Suur osa 
patsientidest ei saavuta täielikku remissiooni erinevatel põhjustel, mille hulka 
kuuluvad ka ravi ebasobivus, ravi kõrvaltoimed, ravi enneaegne lõpetamine jpt. 
Suhteliselt tavapärane on pikaajaline depressioon (kestvusega üle 2 aasta), mis 
on kliiniliselt raskem kui episoodiline depressioon ning sellega kaasneb enam 
igapäevase toimetuleku langust ning kõrvalabivajadust. Kuna depressiooni 
sümptomid suurenevad kooskõlas PT progresseerumisega, suurendavad need ka 
otseseid tervishoiukulusid, (sh uuringud ja ravi) ning kaudseid kulusid (sh 
puudega tekkega seotud töökohakaotus, suurenenud hoolduskoormus) (Huse et 
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al., 2005; Johnson et al., 2013). Neid järeldusi arvestades on kriitilise tähtsusega 
tagada efektiivne ravi alates depressiooni esimesest episoodist. Nagu Weintraub 
(2020) kokku võttis, on mittemotoorsete sümptomite neuraalseks substraadiks 
PT-s haiguse patoloogia, raviefektide, mitmete neurotransmittersüsteemide ja 
närviringetes esinevate muutuste ning geneetiliste mõjude keerukas ja mitme-
tahuline koostoime. PT-ga seotud mittemotoorsed probleemid on seotud liigse 
puude, halvema elukvaliteedi, kehvemate näitajate (sh haigestumus ja suremus) 
ning suurema hoolduskoormusega. PT mittemotoorsete sümptomite praegused 
ravivõimalused on endiselt oma potentsiaalselt kasuliku mõju osas üsna piira-
tud. Paljude peamiste neuropsühhiaatriliste häirete (nt depressioon, kognitiivsed 
häired ja psühhoos) korral on tõendeid nende puuduliku äratundmise ja käsit-
luse kohta (Shulman et al., 2002; Chaudhuri et al., 2020). 
Kuigi PT-d peetakse endiselt liigutushäireks ja seda diagnoositakse peami-
selt motoorsete tunnuste ja sümptomite põhjal (Postuma et al., 2015), viitab 
neuropsühhiaatriliste sümptomite suur levimus sellele, et seda võib klassifitsee-
rida ka neuropsühhiaatrilise häirena (Weintraub & Burn, 2011). Nagu on 
kirjeldanud Gallagher ja Schrag (2012), on neuropsühhiaatriliste sümptomite 
patofüsioloogia keeruline, kajastades PT-s laialt levinud ajutüve ja ajukoore 
patoloogiat, mis hõlmab mitmeid neurotransmittereid (sh dopamiinergilisi, 
serotonergilisi, noradrenergilisi ja kolinergilisi süsteeme). Psühhiaatriliste 
seisundite, eriti emotsionaalsete häirete diagnoosimine on keeruline, kuna 
psühhiaatriliste häirete somaatilised tunnused võivad osaliselt kattuda aluseks 
oleva liigutushäirega. PT ja depressiooniga patsientide abistamiseks on aren-
datud mitu raviviisi, teiste hulgas farmakoteraapia, psühhoteraapia ja ajustimu-
latsioon. Multimorbiidsed, mitut ravimit samaaegselt kasutavad PT patsiendid 
kujutavad endast olulist väljakutset terapeutilise ohutuse ja ravivastuse saavu-
tamisel (Chen & Cheng, 2008). Kõige tavapärasem depressiooniravi kujutab 
endast farmakoloogilist sekkumist, samuti kasutatakse ka psühhoteraapiat. 
Uuem lähenemine depressiooni etioloogias postuleerib, et neuropsühhiaatrilised 
sümptomid tulenevad konkreetsete ajupiirkondade ja/või -võrgustike elektrilise 
aktiivsuse häiritusest (Holtzheimer jt., 2018). Kortikaalset düsfunktsiooni on PT 
puhul dokumenteeritud neurokuvamuslike ja -füsioloogiliste uuringutega, mis 
on viidanud erinevate ajupiirkondade hüpo- või hüperaktivatsioonile (Le-
faucheur, 2006; Lefaucheur, 2009). Üks võimalus aju elektrilise aktiivsuse 
moduleerimiseks on kasutada ajustimulatsiooni. Nii invasiivsed kui ka mitte-
invasiivsed ajustimulatsioonimeetodid võivad neurofüsioloogiliste omaduste 
tasakaalutust korrigeerida. Mitteinvasiivsed ajustimulatsioonimeetodid nagu 
korduv transkraniaalne magnetiline stimulatsioon (rTMS) ja transkraniaalne 
alalisvoolustimulatsioon (tDCS) on näidanud võimekust mõjutada frontostria-
taalse närvivõrgustiku tööd dorsolateraalse prefrontaalkoore (DLPFK) stimulee-
rimise kaudu (Kanno et al., 2004; Marcolin & Padberg, 2007), leevendades 
seeläbi nii nii emotsionaalseid kui kognitiivseid sümptomeid (Schulz et al., 
2013). Transkraniaalse magnetstimulatsiooni (TMS) tööprintsiibiks on lühikeste 
magnetimpulsside suunamine läbi peanaha ja kolju eesmärgiga indutseerida 
huvipakkuva ajupiirkonna kortikaalsete neuronite laenglemist; rTMS on see-
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juures magnetimpulsside kogumite järjestikune kiire esitamine. Nüüdseks on 
juba suur hulk uuringuid analüüsinud rTMS-i kui uurimisvahendit ning mitme-
suguste neuroloogiliste ja psühhiaatriliste häirete potentsiaalset ravi (Kamble et 
al., 2014). Alates USA Toidu- ja Ravimiameti loaandmisest raviresistentse (uni-
polaarse) depressiooni raviks 2008. aastal on rTMSi aktiivselt rakendatud erine-
vate neuropsühhiaatriliste häirete, sealhulgas PT-ga seotud sümptomite leeven-
damiseks.  
Käesoleva doktoritöö peamine eesmärk oli koondada ja laiendada teadmisi 
tõhusa rTMS ravi kohaldamise kohta patsientidel, kellel on diagnoositud nii PT 
kui ka depressioon, hõlmates potentsiaalseid mõjutusi ka väljaspool meele-
oluhäiret (näiteks kognitiivsed probleemid ja ärevushäired) ning kaardistada 
seeläbi võimalikke efekte inimese elukvaliteedile. Protseduur oli kolme-
etapiline: a) analüüsiti saadaolevaid teadmisi depressiooni närviringide kohta 
ning valideeriti need PT kontekstis, b) analüüsiti rTMSi kasutatavust ja raken-
duslikke parameetreid depressiooni ravis PT patsientidel ja c) rakendati kahes 
eelmises punktis saadud teadmisi kliiniliselt keeruka PT-ga patsiendivalimi peal 
(hõlmates inimesi, kel on muu hulgas diagnoositud raviresistentne depressioon), 
eesmärgiga hinnata individuaalsete erinevuste rolli ravivastuses ja koguda 
andmeid praktiliste probleemide kohta ravimeetodi kasutamisel eelkirjeldatud 
kliinilises kontekstis. Eksperimentaalset uuringuprotokolli käsitleti piloot-
mudelina, mida saaks hiljem aluseks võtta optimaalse raviprotokolli väljatööta-
misel PT-ga seotud raviresistentse depressiooni leevendamiseks.  
Doktoritöös käsitletavateks uurimisküsimusteks olid: 
 1. Milline on praegune teaduslik arusaam depressiooni olulisemarest närvi-
võrgustikest PT kontekstis? 
 2. Kuidas mõjutab depressioon PT-ga patsientide üldist haiguse trajektoori ja 
elukvaliteeti? 
 3. Kuidas rTMSi efektiivselt, turvaliselt ning patsiendile talutavalt rakendada 
depressiooni raviks PT kontekstis? Kas lisaks depressiooni ravile on 
tõendeid ka teiste PT-ga seotud neuropsühhiaatriliste probleemide ravimise 
kohta rTMS-i abil? 
 4. Mida silmas pidada, kui kasutada rTMSi raviresistentse depressiooni ravis 
PT kontekstis? Kuidas saab raviprotsessi parimate võimalike tulemuste 
saavutamiseks optimeerida? 
Küsimustele vastamiseks planeeriti ja viidi läbi uuringud. Doktoritöö I uuringu 
eesmärk oli kirjeldada depressioonisümptomite levimust ja raskusastet PT 
patsientidel ning analüüsida võimalikke seoseid konkreetsete ajupõhiste bio-
markerite − antud juhul ajutüve raphe-tuumade sonograafiliste uuringute 
tulemuste − ja depressioonisümptomite vahel. Peamine ootus uurimistööle oli 
leida kinnitus, et raphe-tuumade neuroanatoomilised muutused (väljendatud 
ehhogeensuse tasemetena transkraniaalses ultrahelis) on seotud PD-ga seotud 
depressiooni patogeneesiga ning eelmainitud muutuste määr on otseselt seotud 
depressiooni sümptomite raskusastmega. Arvestades, et depressioonisümpto-
mite raskusaste on oluline PD kliiniliste aspektide mõjutegur, rõhutab see 
vajadust uute tõhusate ravimeetodite järele (eriti raviresistentse depressiooniga 
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PT patsiente silmas pidades). Dorsolateraalse prefrontaalkoore (DLPFK) hüpo-
aktiivsust depressioonis on leidnud mitmed varasemad uuringud ja seda pee-
takse nüüdseks depressiooni oluliseks neurofüsioloogiliseks tunnuseks (Ring jt., 
1994; Dragaševic jt., 2002; Mottaghy jt., 2002; Fregni jt., 2006; Cardoso jt., 
2008; Bench jt., 2009; Koenings ja Grafman, 2009). DLPFK-d kui stimulee-
ritavat ajupiirkonda peetakse rTMS-i ravis kõige ligipääsetavamaks (Wasser-
mann & Lisanby, 2001). II uuringu eesmärk oligi koondada olemasolev 
teaduskirjandus rTMS terapeutilise kasutamise kohta PD neuropsühhiaatriliste 
sümptomite ravi kontekstis, mis on eelkõige seotud DLPFKʼga (s.t. depressioon 
ja kognitiivsed häired). I ja II uuringu käigus saadud teadmistele tuginedes oli 
III uuringu eesmärgiks disainida esialgne, maksimaalselt efektiivne, ohutu ja 
inimesele talutav rTMS-protokoll raviresistentse depressiooniga PT patsien-
tidele. Vastav patsiendigrupp kujutab endast keerukat kliinilist valimit, keda 
iseloomustab suur individuaalne variatiivsus nii kliinilises seisundis kui ka 
võimalikus ravivastuses. Uuringuprotokolli kirjeldamisel püüti võtta neid 
omadusi arvesse, et see saaks olla võimaliku raviviivisi aluseks PT-ga seotud 
raviresistentse depressiooni käsitlemisel edaspidi. 
Kuigi levodopast on abi depressiooni ravimisel väikesele osale PT-patsien-
tidest, ei näita enamik neist ainuüksi sellele ravile kiiret vastust. Depressioon on 
seotud erinevate neurotransmitterite, sealhulgas serotoniini aktiivsusmustriga. 
Nagu on näidatud selle väitekirja I uuringu tulemustes, hävivad PT puhul 
ajutüve raphe-tuumade serotonergilised projektsioonid neurodegeneratsiooni 
tõttu, mis võib olla PT-ga seotud depressiooni etioloogias üks olulisi põhjus-
likke tegureid (Okun & Watts, 2002). Nii primaarse kui ka PT-ga seotud 
depressiooniga patsientidel on neuroanatoomilisi muutusi ajütüve piirkonnas 
(aju keskjoone tasemel) tuvastatud nii magnetresonantstomograafias kui ka 
transkraniaalses sonograafias, toetades meeleoluhäirete korral arusaama raphe 
tuumade olulisust (Berg jt., 2001; Toomsoo jt., 2017). Depressioon on pika-
ajaline ja episoodilise iseloomuga seisund, millel on kalduvus kroonilisusele. 
Kahjuks ei saavuta paljud patsiendid täielikku remissiooni ja seda erinevatel 
põhjustel, mida käesolevas doktoritöös lähemalt ka analüüsitakse. Vaatamata 
PT-ga seotud depressiooni uuringute märkimisväärsele arvule ei ole selle hai-
guse täpne roll PT kontekstis piisavalt mõistetud ega sellele vastavad ravi-
meetodid rahuldavalt välja arendatud. Tavapärane antidepressantravi ei pruugi 
aidata saavutada ootuspäraseid tulemusi. rTMS on väljakujunenud viis aju 
elektrilise aktiivsuse mitteinvasiivseks mõjutamiseks. Uuringud, mis hõlmavad 
rTMS-i PT-ga seotud neuropsühhiaatriliste sümptomite leevendamiseks, on 
üsna napid. Depressiooniga PT patsientidele sobivate stimulatsioonipara-
meetrite täpne kombinatsioon oli alles hiljuti kindlaks tegemata. II uuringu 
tulemusel koguti ja süstematiseeriti praktilisi teadmisi rTMS-i kasutamise 
kohta PT puhul sagedamini esinevate neuropsühhiaatriliste probleemide ravis. 
Üks tõekspidamisi oli see, et ravi tulemus sõltub mitmetest teguritest ja nende 
omavahelisest vastasmõjust. Varasemad uuringud on tuvastanud mitu tegurit, 
sealhulgas naissugu, vanem vanus, üksielamine, madalam haridustase, füüsi-
lised (somaatilised) haigused, depressioon perekonnas, kognitiivsed häired, 
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suitsetamine, alkoholi liigtarvitamine, varase lapseea raskused, isiksuseomadu-
sed ning hiljutised elusündmused, mis võivad mõjutada depressiooni kulgu PT-
ga inimestel (Global Parkinson Disease Survey Steering Committee, 2002; 
Schrag, 2006; Reijnders jt., 2008; Leentjens jt., 2013). III uuring esitas esi-
algsed tõendid rTMS-i rakendamise kohta, mis võiksid sobida kliiniliselt väga 
keerukatele PT-ga patsientidele, sh neile, kellel on raviresistentne depressioon 
ja/või muud neuropsühhiaatrilised ja kaasuvad somaatilised haigused. 
PT-ga patsientide depressiooni kuluga seotud tegurite kindlakstegemine 
võib aidata luua haiguse süvenemist ennetavaid sekkumisi (Sagna et al., 2014). 
Käesolev doktoritöö on aidanud kaasa sedalaadi mõjutavate riskifaktorite välja-
selgitamisele ja optimaalsete ajustimulatsiooniparameetrite tuvastamisele PT-ga 
seotud depressiooni ravi efektiivsuse parendamiseks ja raviresistentsuse ületa-
miseks, pakkudes teaduslikult argumenteeritult lähenemisviisi, mis sünteesib 
uusimaid kliinilisi tõendeid mitteinvasiivse ajustimulatsiooni rakendamisest ja 
seostamisest traditsioonilisemate sekkumistega. Kuigi objektiivsete kliiniliste 
näitajate märkimisväärset paranemist on sageli keeruline saavutada, on elu-
kvaliteedialaste näitajate suurenemist täheldatud üha enamates kliinilistes uurin-
gutes. See tekitab vajaduse jätkata elukvaliteedialaste näitajate mõõtmist uurin-
gutes, mille eesmärgiks on ravida neurodegeneratsiooniga seotud neuropsüh-
hiaatrilisi sümptomeid ajustimulatsioonimeetodite abil. Sellist lähenemist illust-
reerivat empiirilist uurimist püüti rakendada ka käesoleva doktoritöö eksperi-
mentaalses osas. rTMSi potentsiaalse kasulikkuse täpsustamiseks PD-ga seotud 
neuropsühhiaatriliste sümptomite korral on soovitatav lähtuda teaduspõhistest 
alustest. Erinevate ajupiirkondade stimuleerimine erinevates kortikaalsetes kih-
tides, erinevad stimulatsiooniparameetrid ajustimulatsiooni kombineerimine 
teiste (farmakoloogiliste ja mittefarmakoloogiliste) sekkumistega jm metodo-
loogilised aspektid nõuavad edasisi pikaajalisi mahukaid kliinilisi uuringuid, et 
täpsustada sekkumiste mõjusid ja koostoimeid ning neid optimeerida. Väite-
kirjas sisalduvate uuringute kokkuvõttena saab esitada järgnevad väited: 
 1. Depressioonisümptomite raskusaste on oluline PT kliinilisi aspekte ja 
patsientide elukvaliteeti mõjutav tegur. Ajutüve raphe-tuumade neuroana-
toomilised muutused on otseselt seotud depressioonihäirete patogeneesiga 
ning rõhutavad depressiooni neurokuvamuslike biomarkerite kasvavat 
tähtsust ja diagnostilist rakendatavust PT kontekstis. 
 2. DLPFK stimuleerimine rTMS-ga on efektiivne PT-ga seotud depressiooni 
ravistrateegia, kusjuures võimalik on ka positiivne mõju teistele neuro-
psühhiaatrilistele probleemidele (nt kognitiivsed häired, ärevushäired, apaat-
sus) − viimaste osas on vajalikud kinnitused edaspidistes kliinilistes uurin-
gutes.  
 3. Raviresistentse depressiooniga PT patsiendid kujutavad endast keerukat 
kliinilist valimit, millel on palju, sageli ebapiisavalt kaetud ravivajadusi. See 
rõhutab vajadust arvesse võtta individuaalset varieeruvust nii kliinilises sei-
sundis kui ka võimalikus ravivastuses ja õigustab seeläbi isikupärastatavaid 
ravialaseid sekkumisviise, mille hulka sobib nii eraldivõetuna kui ka teiste 















































Name:  René Randver 
Date of Birth:  November 17, 1983 




2013–2021 University of Tartu – Psychology (PhD) 
2009–2011 University of Maastricht, Netherlands – Neuropsychology 
(MSc) 
2009 University of Melbourne, Australia (one semester) 
2008–2011 University of Tartu – Biomedical Sciences (MSc) 
2005–2008 University of Tartu – Psychology (BA) 




2013– Neura – CEO and Clinical Neuropsychologist 
2021–2021  Estonian Health Insurance Fund, Dept. of Innovation –  
Project Manager 
2020–2021  MinuDoc – Mental Health Service Manager 
2019–2021  SENSUS Psychiatry and Psychotherapy Center –  
Clinical Neuropsychologist 
2018–2020 Ministry of Social Affairs, Dept. of Social Welfare – Adviser 
2018–2018 4 Clinic, Psychiatry Center and Sleep Center –  
Clinical Neuropsychologist 
2017–2019 University of Tartu, Institute of Psychology –  
Junior Research Fellow 
2013–2016 Cognuse – Consultant and Member of the Scientific Advisory 
Board 




 − Clinical Psychologist, Clinical Neuropsychologist – Union of Estonian 
Psychologists 
 − European Certificate in Psychology (field: clinical and health psychology) – 










Membership in professional organizations: 
2014–  Estonian Association of Gerontology and Geriatrics  
2013–  American Psychological Association, Society for Clinical 
Neuropsychology 
2013–  International Neuropsychological Society 
2018–2020 Alzheimer Europe Group of Governmental Experts on 
Dementia National Representative (Estonia) 
2013–2021 Doctoral School of Behavioural, Social and Health Sciences 
 
Volunteering: 
2017–  NGO Life with Dementia – Member 
2016–2016 Estonian Dementia Special Interest Group – Co-founder 
2015–2019 International Neuroopsychological Society – Local 
Representative in Estonia 
2010–2011 AIESEC Estonia, Tartu Office – Public Relations Officer 
Project “World at Home” 
 
Publications: 
1.  Toomsoo, T., Randver, R., Liepelt-Scarfone, I., Kadastik-Eerme, L., Asser, 
T., Rubanovits, I., ... & Taba, P. (2017). Prevalence of depressive symptoms 
and their association with brainstem raphe echogenicity in patients with 
Parkinsonʼs disease and non-PD controls. Psychiatry Research: Neuro-
imaging, 268, 45–49.  
  https://www.sciencedirect.com/science/article/abs/pii/S092549271730032X 
2.  Randver, R. (2018). Repetitive transcranial magnetic stimulation of the 
dorsolateral prefrontal cortex to alleviate depression and cognitive impair-
ment associated with Parkinsonʼs disease: A review and clinical impli-
cations. Journal of the Neurological Sciences, 393, 88–99.  
 https://www.sciencedirect.com/science/article/abs/pii/S0022510X18303356 
3.  Randver, R., Davel, K., & Toomsoo, T. (2019). High-frequency repetitive 
transcranial magnetic stimulation to the left dorsolateral prefrontal cortex of 
patients with Parkinsonʼs disease and treatment-resistant depression: a pilot 
study. Neurocase, 25(3–4), 80–90.  
 https://www.tandfonline.com/doi/abs/10.1080/13554794.2019.1636069 
4. Randver, R., Vahter, L., & Ennok, M. (2015). Neuropsychological Services 






Nimi: René Randver 
Sünniaeg: November 17, 1983 




2013–2021     Tartu Ülikool, psühholoogia, doktorikraad 
2009–2011     Maastricht'i Ülikool, Holland, neuropsühholoogia, magistrikraad 
(MSc) 
2009               Melbourne'i Ülikool, Austraalia (vahetussemester) 
2008–2011     Tartu Ülikool, biomeditsiin, magistrikraad (MSc) 
2005–2008     Tartu Ülikool, psühholoogia, bakalaureusekraad (BA) 
1999–2002     Tallinna Nõmme Gümnaasium (reaalharu), keskharidus 
 
Teenistuskäik: 
2013–  Neura – Tegevjuht, neuropsühholoog 
2021–2021  Eesti Haigekassa, Innovatsiooniosakond – Projektijuht 
2020–2021  MinuDoc – Vaimse tervise teenusejuht 
2019–2021  Psühhiaatria ja Psühhoteraapiakeskus SENSUS – 
Neuropsühholoog 
2018–2020 Sotsiaalministeerium, Hoolekande osakond – Nõunik 
2018–2018 4 Kliinik, Psühhiaatriakeskus, Hea Une Keskus – 
Neuropsühholoog 
2017–2019 Tartu Ülikool, Psühholoogia Instituut – Nooremteadur 
2013–2016 Cognuse – Konsultant, teadusnõukoja liige 
2011–2018 Ida-Tallinna Keskhaigla, Neuroloogiakeskus – Neuropsühholoog 
 
Erialasertifikaadid: 
 − Kliiniline psühholoog, tase 7 ja neuropsühholoog, tase 7 – Eesti 
Psühholoogide Liit 
 − Euroopa sertifikaat psühholoogias (EuroPsy; valdkond: kliiniline ja 
tervisepsühholoogia) – European Federation of Psychologistsʼ Associations 
 
Liikmelisus erialastes organisatsioonides: 
2014–  Eesti Gerontoloogia ja Geriaatria Assotsiatsioon (EGGA) 
2013–  Ameerika Psühholoogiaassotsiatsioon (APA), 
 Kliinilise neuropsühholoogia ühing (SCN) 
2013–  Rahvusvaheline Neuropsühholoogiaühing (INS) 
2018–2020 Alzheimer Europe riiklike dementsuse ekspertide töögrupp 




2017–  MTÜ Elu dementsusega – liige 
2016/03–2016/09 Dementsuse töögrupp – kaasasutaja 
2015–2019 Rahvusvaheline Neuropsühholoogiaühing (INS) – Eesti 
esindaja 
2010–2011 AIESEC Eesti, Tartu osakond – Avalike suhete korraldaja 
 Projekt “World at Home” 
 
Publikatsioonid: 
1.  Toomsoo, T., Randver, R., Liepelt-Scarfone, I., Kadastik-Eerme, L., Asser, 
T., Rubanovits, I., ... & Taba, P. (2017). Prevalence of depressive symptoms 
and their association with brainstem raphe echogenicity in patients with 
Parkinsonʼs disease and non-PD controls. Psychiatry Research: Neuro-
imaging, 268, 45–49.  
 https://www.sciencedirect.com/science/article/abs/pii/S092549271730032X 
2. Randver, R. (2018). Repetitive transcranial magnetic stimulation of the 
dorsolateral prefrontal cortex to alleviate depression and cognitive impair-
ment associated with Parkinsonʼs disease: A review and clinical implica-
tions. Journal of the Neurological Sciences, 393, 88–99.  
 https://www.sciencedirect.com/science/article/abs/pii/S0022510X18303356 
3.  Randver, R., Davel, K., & Toomsoo, T. (2019). High-frequency repetitive 
transcranial magnetic stimulation to the left dorsolateral prefrontal cortex of 
patients with Parkinsonʼs disease and treatment-resistant depression: a pilot 
study. Neurocase, 25(3–4), 80–90.  
 https://www.tandfonline.com/doi/abs/10.1080/13554794.2019.1636069 
4.  Randver, R., Vahter, L., & Ennok, M. (2015). Neuropsychological Services 




DISSERTATIONES PSYCHOLOGICAE  
UNIVERSITATIS TARTUENSIS 
1. Jüri Kruusvall. Environmental and social influence on human activity. 
Tartu, 1994, 135 p. 
2. Dagmar Kutsar. Transformation in Estonia as reflected in families: Insight 
into social stress and poverty. Tartu, 1995, 171 p. 
3. Aleksander Pulver. Measurement of elementary movement vectors in 
human visual system. Tartu, 1995, 123 p. 
4. Ritva Fagerström. The correlations between psychological factors and 
vision in aged cataract operation patients. Tartu, 1996, 145 p. 
5. Eve Kikas. Conceptual development in school-aged children: The impact 
of teaching. Tartu, 1997, 112 p. 
6. Anu Realo. Individualism and collectivism: An exploration of individual 
and cultural differences. Tartu, 1999, 164 p. 
7. Aaro Toomela. Cultural-historical psychology: three levels of analysis. 
Tartu, 2000, 171 p. 
8. Anneli Kolk. Cognitive development of children with non-progressive 
unilateral brain lesion. Tartu 2001, 95 p. 
9. Aune Valk. Two facets of ethnic identity: pride and differentiation. Tartu, 
2001, 153 p. 
10. Anu Aluoja. Depression in the population: assessment, prevalence and 
relationships with socio-demographic factors and cognitive aspect of social 
adjustment. Tartu 2002, 73 p. 
11. Talvi Kallasmaa. Personality traits and ways of coping: their characte-
ristics and interrelations. Tartu 2002, 119 p. 
12. Luule Mizera. Socialization in Estonian families: attitudes and behavior in 
comparative perspective. Tartu 2003, 117 p. 
13. Kairi Kreegipuu. Availability and accessibility of information in per-
ception of moving stimuli. Tartu 2004, 97 p. 
14. Riina Häidkind. Monoaminergic mechanisms in mood-associated beha-
viours and neurochemistry in rats. Tartu 2004, 123 p. 
15. Evelyn Kiive. Studies on peripheral markers of central serotonergic activity 
and behaviour. Tartu, 2005, 113 p. 
16. Helle Pullmann. The development of intelligence and personality traits 
among Estonian schoolchildren. Tartu, 2005, 112 p.  
17.  Kenn Konstabel. The structure and validity of self- and peer-reported per-
sonality traits. Tartu, 2006, 103 p. 
18. Toivo Aavik. Lexical analysis of Estonian personal values vocabulary and 
relation to socially desirable responding and parenting practices. Tartu, 
2006, 113 p.  
19.  Margus Tõnissaar. Stress and sociability: individual differences and their 
neurochemical substrate. Tartu, 2006, 161 p. 
125 
20.  Kaia Laidra. Adolescent personality: Development, interrater agreement, 
and relation to academic achievement. Tartu, 2007, 117 p.  
21.  Iiris Luiga. Interaction of object perception and visual attentional selection 
processes. Tartu, 2007, 116 p. 
22.  Marika Paaver. Types of impulsivity, their behavioural expression, and 
association with the markers of vulnerability of serotonin system. Tartu, 
2007, 140 p. 
23.  Tanel Mällo. Exploratory behaviour and 50-kHz ultrasonic vocalizations 
in rats: behavioural and neurochemical profiles of persistent inter-indi-
vidual differences. Tartu, 2008, 216 p. 
24. Aet Alttoa. Neurochemical regulation of rat exploratory behaviour: focus 
on dopaminergic and noradrenergic neurotransmission. Tartu, 2008, 166 p.  
25.  René Mõttus. Universal and specific features of personality traits in their 
various representations. Tartu, 2009, 170 p. 
26. Kirsti Akkermann. Serotonin-related biomarkers and symptoms of eating 
disorders. Tartu, 2010, 120 p. 
27.  Iris Podar. Eating disorders, personality, and cultural differences. Tartu, 
2010, 130 p. 
28.  Denis Matrov. Cerebral oxidative metabolism and effects of chronic vari-
able stress in animal models of human affective styles. Tartu, 2010. 208 p. 
29.  Kadri Kõiv. Studies on monoaminergic regulation of inter-individual 
differences in exploratory behaviour and the activating and rewarding 
effects of psychostimulants in rats. Tartu, 2010, 132 p. 
30. Triin Hannust. Children’s knowledge about the Earth and gravity and its 
change in the course of development and learning. Tartu, 2011, 108 p. 
31.  Kersti Luuk. Antecedents and concomitants of adult psychological 
distress. Tartu, 2011, 132 p. 
32.  Margus Kanarik. Inter-individual differences in vulnerability to depres-
sion: regional brain energy metabolism, serotonergic function and be-
haviour in animal models. Tartu, 2011, 239 p. 
33.  Aire Raidvee. Pooling of elementary motion, colour, and orientation 
signals into global perception. Tartu, 2012, 105 p. 
34.  Liisi Kööts-Ausmees. Emotional experience: relations to personality, sub-
jective well-being, recollection, and external influences. Tartu, 2012,  
137 p. 
35.  Pirko Tõugu. “Where did we go last weekend?” Socialization of children 
through past-event reminiscing in various cultural contexts. Tartu, 2012,  
132 p. 
36.  Triin Kurrikoff. Interpersonal relationships and behaviour: moderation by 
functional gene variants. Tartu, 2012, 126 p. 
37.  Karin Täht. The cross-cultural view on students’ motivation to learn. 
Tartu, 2012, 137 p. 
38. Henrik Dobewall. Human values and subjective well-being: An ex-
ploration of individual and cultural differences, change across life span, 
and self-other agreement. Tartu, 2013, 157 p.  
126 
39. Carolina Murd. Mechanisms of processing visual motion information: 
Psychophysical, bioelectrical and transcranial magnetic stimulation in-
vestigations. Tartu, 2014, 120 p. 
40. Andero Uusberg. Electroencephalographic insights into affective attention. 
Tartu, 2014, 122 p. 
41. Kariina Laas. Neuropeptide S and mental health: A functional receptor 
gene variant and environment shaping traits and contributing to psychiatric 
disorders. Tartu, 2014, 144 p. 
42.  Maria Tamm. Psychological and physiological implications of time per-
ception. Tartu, 2014, 154 p.  
43. Inga Karton. Deceptive communication: the effects of transcranial mag-
netic stimulation and the signatures of electroencephalography. Tartu, 
2014, 94 p. 
44. Kelli Lehto. Depression- and anxiety-related gene variants: effects on 
personality traits and health-related behaviour. Tartu, 2015, 104 p. 
45.  Anni Tamm. Conflicts and their management in early childhood and adole- 
scence. Tartu, 2015, 161 p. 
46.  Renate Rutiku. Refining the methodology for investigating the neural 
correlates of consciousness. Tartu, 2015, 166 p. 
47. Uku Vainik. Towards a comprehensive framework for the psychological 
mechanisms of obesity and overeating. Tartu, 2015, 152 p.  
48.  Mari-Liis Kaldoja. Mild traumatic brain injury in childhood: pre-injury 
social-emotional behavior, social-emotional and cognitive outcome and 
implications for attention rehabilitation. Tartu, 2015, 135 p. 
49. Astra Schults. First words of Estonian children: early communicative 
development. Tartu, 2016, 109 p. 
50.  Mariliis Vaht. Genes and alcohol use: effects of common genetic poly-
morphisms in general population. Tartu, 2016, 120 p. 
51.  Aire Mill. Exploring the role of personality traits and age in the experience 
and recognition of emotions. Tartu, 2017, 148 p. 
52.  Nele Põldver. An experimental exploration of automatic processes in 
visual perception. Tartu, 2018, 153 p. 
53. Helen Uusberg. Studying the psychological mechanisms of affective 
individual differences with EEG correlates. Tartu, 2018, 177 p. 
54. Jaan Tulviste. Modulation of decision-making by transcranial magnetic 
stimulation. Tartu, 2019, 83 p. 
55. Dmitri Rozgonjuk. Problematic smartphone use: behavioral, psychopatho-
logical, dispositional, and educational correlates. Tartu, 2019, 116 p. 
56.  Kadi Tulver. An investigation of individual differences in the effects of 
priors on visual perception. Tartu, 2019, 108 p. 
57.  Katrin Kukk. Risk factors of binge eating and overeating – towards an 
integrated model. Tartu, 2020, 114 p. 
58.  Gerly Tamm. Multiple sources of variation in perception and working 
memory for facial emotional expressions. Tartu, 2021, 217 p. 
 
